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Abstract 
  G protein-coupled receptors (GPCRs) are the largest family of proteins 
within the human genome. They consist of seven transmembrane (TM) helices, with a N-
terminal region of varying length and structure on the extracellular side, and a C-terminus 
on the intracellular side. GPCRs are involved in transmitting extracellular signals to cells, 
and as such are crucial drug targets. Designing pharmaceuticals to target GPCRs is greatly 
aided by full-atom structural information of the proteins. In particular, the TM region of 
GPCRs is where small molecule ligands (much more bioavailable than peptide ligands) 
typically bind to the receptors. In recent years nearly thirty distinct GPCR TM regions have 
been crystallized. However, there are more than 1,000 GPCRs, leaving the vast majority of 
GPCRs with limited structural information. Additionally, GPCRs are known to exist in a 
myriad of conformational states in the body, rendering the static x-ray crystal structures an 
incomplete reflection of GPCR structures. In order to obtain an ensemble of GPCR 
structures, we have developed the GEnSeMBLE procedure to rapidly sample a large 
number of variations of GPCR helix rotations and tilts. The lowest energy GEnSeMBLE 
structures are then docked to small molecule ligands and optimized. The GPCR family 
consists of five subfamilies with little to no sequence homology between them: class A, B1, 
B2, C, and Frizzled/Taste2. Almost all of the GPCR crystal structures have been of class A 
GPCRs, and much is known about their conserved interactions and binding sites. In this 
work we particularly focus on class B1 GPCRs, and aim to understand that family’s 
interactions and binding sites both to small molecules and their native peptide ligands. 
Specifically, we predict the full atom structure and peptide binding site of the glucagon-like 
peptide receptor and the TM region and small molecule binding sites for eight other class 
B1 GPCRs: CALRL, CRFR1, GIPR, GLR, PACR, PTH1R, VIPR1, and VIPR2. Our class 
B1 work reveals multiple conserved interactions across the B1 subfamily as well as a 
consistent small molecule binding site centrally located in the TM bundle. Both the 
interactions and the binding sites are distinct from those seen in the more well-
characterized class A GPCRs, and as such our work provides a strong starting point for 
drug design targeting class B1 proteins. We also predict the full structure of CXCR4 bound 
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to a small molecule, a class A GPCR that was not closely related to any of the class A 
GPCRs at the time of the work. 
 vii 
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Background 
 
G Protein Coupled Receptors 
 G protein coupled receptors (GPCRs) are the largest protein superfamily in 
mammalian genomes.1 They are integral membrane proteins that enable cells to respond 
to external stimuli. Because of their vital role in cellular signaling networks, GPCRs are 
involved in many diseases, and are the target of approximately 40% of all prescription 
pharmaceuticals on the market.2  
 GPCRs are activated by intercellular signaling molecules such as hormones, 
neurotransmitters, ions, and chemokines, or they sense light, or odorants, or taste 
substances (Figure 1). Upon interaction with their signaling molecules, GPCRs undergo 
conformational changes, which catalyze GDP-GTP (guanosine triphosphate-guanosine 
diphosphate) exchange on the heterotrimeric G proteins.3 This starts a signaling cascade 
through which the G proteins affect cell metabolism in two major ways: regulation 
(activation/inhibition) of cyclic AMP (adenosine monophosphate) concentration or 
stimulation of inositol phospholipid hydrolysis.4 Each of these responses cause further 
cellular reactions, the specifics of which depend on the cell signaling pathways involved. 
GPCRs share a common architecture of seven transmembrane (TM) domains. These 
α-helical domains are roughly 20-30 amino acids long and are arranged in a tightly 
packed bundle.5 The N terminus of the protein is located in the extracellular space while 
the C terminus is in the intracellular area. The seven transmembrane helices are 
connected by six alternating intracellular (IC1-3) and extracellular (EC1-3) loops. 
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Figure 1. Diversity of G-protein-coupled receptor cell signaling pathways. 
Abbreviations: DAG: diacylglycerol, FSH: follicle-stimulating hormone, GEF: guanine 
nucleotide exchange factor, LH: luteinizing hormone, LPA: lysophosphatidic acid, PAF: 
platelet-activating factor, PI3K:  phosphoinositide 3-kinase, PKC: protein kinase C, PLC:  
phospholipase C, S1P: sphingosine-1-phosphate, TSH: thyroid-stimulating hormone.6 
 
 
Classes of GPCRs 
 A phylogenetic analysis of GPCRs splits the family into five classes: class A 
(rhodopsin-like), class B1 (secretin-like), class B2 (adhesion-like), class C (glutamate-
like), and Frizzled/Taste2.7 The classes share little to no sequence homology, but share 
similar transmembrane domain architectures and interact with the same G proteins. The 
N-terminal architecture of the five classes varies wildly, as do the native ligand binding 
sites. Class A GPCRs have short unstructured N-termini (on the order of 30 residues) and 
their native ligands tend to be small molecules that interact within the TM region of the 
proteins (Figure 2A). Class B1 receptors have longer, structured, N-termini (on the order 
of 150 residues), and their endogenous ligands are peptides whose helical portion 
interacts with the N-terminus while a flexible portion of the ligand interacts with the TM 
region (Figure 2B). Class B2 receptors have very large extracellular domains (on the 
order of 950 residues) which contain known protein motifs, and are coupled to the TM 
region by a GPCR-autoproteolisis inducing domain. Their native ligands primarily 
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interact with their large N-termini. Class C GPCRs have large N-termini (on the order of 
600 residues) which consist of a cysteine-rich domain (CRD) above the TM region as 
well as a “Venus fly trap” structured region above the CRD which interacts with their 
small molecule ligands. Frizzled receptors have a large N-terminus (around 300 residues) 
which have a CRD. Their protein ligands are proposed to interact with both the CRD and 
TM regions. Taste2 receptors architectures are architecturally similar to class A GPCRs: 
they have short N-termini (around 10 residues or less) and their native ligands bind 
within the TM region. 
 
 
Figure 2. Typical (A) class A and (B) B1 GPCR endogenous ligand binding sites. The 
N-termini of the class B1 receptors have several α-helices and/or β-sheets, while the N-
termini of the class A GPCRs are unstructured and approximately 100 residues shorter. 
 
 
GPCR Crystal Structures 
 To date, there are approximately thirty GPCR TM region structures (Figure 3).8 
Most have a single structure, although a few class A GPCRs have several, including both 
their active and inactive forms. The majority (22) of the x-ray crystal structures are from 
the class A GPCR family, with two structures from the class B1 family, two from the 
class C family, and one from the Frizzled/TAS2 family.8 In order to obtain these 
structures, modifications are often made to the wild type protein including residue 
mutations or insertion of large structured proteins (T4 Lysozyme or b562RIL) to the 
intracellular loops or N-terminus.9 
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Figure 3. GPCR x-ray crystal structures shown on the GPCR phylogenetic tree. 
Note that the majority (22) of the structures are from the class A GPCR family (blue 
tree), with two structures from the class B1 family (red tree), two from the class C family 
(orange tree), and one from the frizzled/TAS2 family (green tree).10 
 
 Due to the larger number of x-ray crystal structures available for class A GPCRs, 
several conserved hydrogen bond networks have been discovered. These motifs include 
hydrogen bond networks between residues on TMs 1, 2, and 7 and TMs 2, 3, and 4  
which are highly conserved among Class A GPCRs (Figure 4A). Additionally, inactive 
crystal structures show an interaction between TMs 3 and 6 (Figure 4B).11 To denote 
residue locations with respect to the TM region’s most conserved residue, Ballesteros 
numbering is utilized.12 The most conserved residue for each helix is designated by its 
helix number followed by .50 (Figure 4C). Other residues are specified by counting up 
or down from 50. The TM 1-2-7 interaction is thus shown: N1.50-D2.50-N7.49, while the 
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TM 2-3-4 interaction is S/N/T3.42-S/N/T2.45-W4.50. The inactive TMs-TM6 interaction 
is usually R3.50-E6.30.  
 
Figure 4.  Class A conserved interactions. (A) The TM region 1-2-7 (N1.50-D2.50-
N7.49) and TM region 2-3-4 (S/N/T3.42-S/N/T2.45-W4.50) conserved hydrogen bond 
networks of Class A GPCRs.13 (B) The conserved TM region 3-6 (R3.50-E6.30) 
interaction which is indicative of an inactive structure. The pictured residues are for 
bovine rhodopsin, and the numbers in red are the Ballesteros numbers. (C)The conserved 
residue motifs of Class A GPCRs. The residues marked in red are those designated as .50 
in Ballesteros numbering.12, 14-15 
 
 
Statement of the Problem 
 Full-atom structures of GPCRs provide great aid to designing drugs that target 
them. However, such information can only be obtained in two ways: x-ray 
crystallography or computational predictions. Unfortunately, GPCRs, like other 
membrane proteins, are notoriously difficult to crystallize. While there has been a marked 
increase in the number of GPCRs crystallized in the last few years, there are still fewer 
than thirty distinct receptors with transmembrane region crystal structures out of the over 
1,000 human GPCRs.8 In order to crystallize these GPCRs modifications are made to the 
wild type protein including residue mutations or insertion of large structured proteins (T4 
Lysozyme or b562RIL) to the intracellular loops or N-terminus.9 These insertions may 
potentially impact the ability of the crystal structure to accurately represent nature. 
Additionally, the majority (22) of the crystallized GPCR structures are of class A GPCRs, 
leaving the other classes, which share no significant sequence homology with class A, 
significantly less well understood. Finally, GPCRs exist in a myriad of activation states in 
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the body, depending on which ligands the protein is interacting with and its activation 
state.16 X-ray crystal structures only provide a snapshot of GPCR structures in specific 
crystallizable environments. Therefore, in order to obtain full-atom structural information 
about an ensemble of GPCR structures, one must turn to computational methods. 
 
Purpose of the Study 
 In this work, we use computational techniques to predict the structures and 
binding sites of GPCRs, with a focus on class B1 GPCRs and transmembrane region 
predictions. The GEnSeMBLE (GPCR Ensemble of Structures in Membrane BiLayer 
Environment) procedure is used to optimize the transmembrane helix bundle. 
Specifically, the possible helix rotations and tilts are explored in great detail. GenDock is 
then utilized to generate small molecule binding site information for the GPCR targets of 
interest. The GPCR structures and binding sites are analyzed with an emphasis on 
conserved interactions in the class B1 family. The peptide binding site to the full TM 
region and N-terminus of the class B1 GPCR GLP1R is generated and compared to class 
A GPCRs and experimental data. Transmembrane region structure and small ligand 
binding sites across the class B1 family are predicted and analyzed for these receptors: 
CALRL, CRFR1, GLR, GIPR, GLP1R, PACR, PTH1R, VIPR1, and VIPR2. Finally, the 
structure and small molecule binding site of CXCR4, a class A GPCR, is also predicted. 
 
Outline of the Thesis 
 
Chapter II: Methodology overview focusing on the GEnSeMBLE procedure of 
predicting an ensemble of GPCR structures and the GenDock hierarchical docking 
program. 
 
Chapter III: Full structural prediction of GLP1R, a class B1 GPCR, bound to Exendin-4, 
a peptide ligand. Interactions between conserved residues are analyzed, as is the peptide 
binding site to both the N-terminus and TM region. Experimental data is used to validate 
the prediction. 
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Chapter IV: Transmembrane region and small-molecule binding site predictions of nine 
class B1 GPCRs: CALRL, CRFR1, GLR, GIPR, GLP1R, PACR, PTH1R, VIPR1, and 
VIPR2. Conserved interactions and binding sites are compared across the B1 subfamily 
of GPCRs. Comparisons to the two x-ray crystal class B1 structures recently released are 
made, and our structure and binding site prediction methods are used on these two 
receptors as well. 
 
Chapter V: Full structural prediction of CXCR4, a class A GPCR, bound to the small 
molecule ligand 1t. Comparisons are made to the later published CXCR4 crystal 
structure. 
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 The following chapter describes the technical details of the methodology used in 
the GEnSeMBLE and GenDOCK procedures. Exceptions and relevant details for each 
specific structural prediction will be noted in its chapter. 
 
GEnSeMBLE: Generating an Ensemble of GPCR Structures 
 The GEnSeMBLE (GPCR Ensemble of Structures in Membrane BiLayer 
Environment) procedure is an ab initio methodology for predicting the multiple 
conformations of the different conformation states of a GPCR.1-5 We refer to this method 
as a first principles one due to its minimal reliance on structural information from 
experimental data. The vast majority of the procedure is based solely from the amino acid 
sequence of the protein. This allows the methodology to be used on proteins of low 
sequence homology to the thirty experimentally determined transmembrane region GPCR 
structures out of the over 1,000 total GPCRs.6 This methodology is particularly useful 
when predicting the structures of non-class A GPCRs, since the vast majority of the 
crystallized structures are those of class A GPCRs, but there is little to no sequence 
homology between the classes.  
 One of the unique strengths of the GEnSeMBLE procedure is its ability to predict 
an ensemble of low-energy structures of GPCRs. GPCRs exist in a myriad of activation 
states in the body, depending on which ligands the protein is interacting with and its 
activation state.4, 7-8 X-ray crystal structures only provide a snapshot of GPCR structures 
in specific crystallizable environments. Additionally, they often have mutations or added 
cofactors to aid in the crystallization process, such as the addition of the T4 lysozyme to 
one of the intracellular loops or the BRIL protein to an intracellular loop or in place of 
the N-terminus of the protein.9 These cofactors, mutations, and the crystal conditions 
themselves may bias GPCR crystal structures away from their real structures in nature. 
The GEnSeMBLE methodology has none of these effects. This fact, plus its ability to 
efficiently predict a myriad of structures of different activation levels, makes the 
GEnSeMBLE procedure ideal for GPCR structure prediction. 
The GEnSeMBLE methodology focuses on the prediction of the seven 
transmembrane (TM) helix bundle of GPCRs. This region is the primary area of 
interaction between small molecule ligands and GPCRs, making a full-atom 
12 
 
understanding of the TM structure essential for rational drug design. Additionally, many 
more crystal structures exist of the water-soluble portions of GPCRs, allowing homology 
modeling to those areas to be more effective. 
 The GEnSeMBLE procedure consists of two main steps (Figure 1): First, the TM 
region locations and lengths are determined via homology modeling and then the TM 
bundle is generated. Next, an ensemble of structures is generated via helix angle 
optimizations in Bihelix/Combihelix and Superbihelix/SuperCombihelix. The ensemble 
of structures generated are then used for docking in the GenDock methodology. 
 The GEnSeMBLE methodology has been validated by predicting several 
crystallized GPCR structures, and we find that our predicted structures are accurate.1-3 
For example, Abrol et al. predicted the inactive human adenosine A2A receptor 
(iAA2AR) conformation starting from the inactive human β2 adrenergic receptor (iβ2AR) 
template using the GEnSeMBLE method. After sampling, the iAA2AR predicted structure 
had a small 1.4 Å backbone root-mean-squared deviation (RMSD) with respect to the 
actual iAA2AR crystal.3 
 
 
Figure 1. GEnSeMBLE overview. The GPCR Ensemble of Structures in Membrane 
BiLayer Environment GPCR structure prediction method samples a large variety of helix 
rotations and tilts, producing an ensemble of GPCR structures. 
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7 TM Helix Bundle Generation 
 The first step in GPCR structure prediction is the determination of the lengths and 
locations of the seven TM helices. This is achieved by homology modeling to the x-ray 
crystal structures with the most closely related sequence to the protein of interest, as 
determined by a ClustalW10 sequence alignment between the target GPCR and all known 
GPCR crystal sequences. Once the target and template sequences are aligned, the helical 
regions are directly determined from those of the crystallized GPCR.  
Before any further steps are taken in the homology modeling process, the selected 
x-ray crystal structures must be prepared for use. This entails removing the GPCR from 
its crystal environment, including any fusion proteins. If any residues are missing or 
unresolved in the crystal structure, they are added in via Schrödinger’s protein building 
tools11-12. The entire bundle is then minimized to 0.5RMS force in MPSim13 using the 
Dreiding14 forcefield and conjugate-gradient minimization (all future minimizations 
mentioned will use this method unless stated otherwise).  
Once the full crystal protein crystal template structure is relaxed, its helical shapes 
and locations (x, y in Figure 1) are used to generate a starting conformation for the target 
protein’s TM bundle. To do this, the helical portions are directly taken from the crystal 
structure. The crystal residues are then mutated to that of the target protein according to 
the previous ClustalW sequence alignment using the side chain optimization program 
SCREAM15. The individual helix backbones are then minimized. After the helices have 
been built they are oriented with respect to each other via the crystal x and y locations. 
The z location is taken from the crystal structure as determined by the Orientations of 
Proteins in Membranes (OPM) database.16  
At the end of this procedure we have a target protein whose helical shapes and 
relative locations are taken directly from that of the GPCR crystal structure (or more 
likely, several of these, one for each crystal template used). The side chains have been 
optimized by SCREAM, and the helix backbones are relaxed slightly from their initial 
individual minimization.  
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7 TM Bundle Optimization 
 After TM bundles are generated, we optimize their angles. First, 
Bihelix/Combihelix1  is used to coarsely optimize the helix rotations (η in Figure 1), then 
Superbihelix/SuperCombihelix5 more finely optimize the helix rotations as well as their 
tilts (θ, φ in Figure 1). All samplings of the rotations and tilts of the helices are 
performed with respect to the least moment of inertia vector for the helix (red arrow in 
Figure 1), obtained by diagonalizing the moment of inertia matrix for the helix using 
only heavy backbone atoms.1 
 
 
Bihelix/Combihelix 
 Bihelix involves sampling η angles in 30° increments to score 127 (~35 million) 
combinations of angles. This procedure independently considers the 12 pairs of helices 
that are close enough to directly interact (1-2, 1-3, 1-7, 2-3, 2-4, 2-7, 3-4, 3-5, 3-6, 3-7, 4-
5, 5-6, and 6-7, pictured in Figure 2). For each of the 122 combinations of each pair, the 
side chains are optimized using SCREAM and are minimized for 10 steps. Summing the 
total intra- and interhelical values from the 123 pairwise interaction energies leads to an 
energy estimate for all ~35 million bundles (a more thorough discussion of the energy 
scoring can be found in our 2012 Bihelix paper, along with validations of the 
methodology1). The Combihelix procedure constructs the 2,000 lowest total energy 
bundles and optimizes them. The energy is evaluated after SCREAM and 10 steps of 
minimization. The bundles with the lowest averaged charged interhelical, charged total, 
neutral interhelical, and neutral total energy ranks continue on to Superbihelix. If bundles 
with different helix lengths are being considered, the average charged interhelical and 
neutral interhelical energy ranks are used instead. The neutral energies mentioned here 
are those obtained by transferring the hydrogen of each charged residue interaction from 
the acceptor to the donor and a modified Dreiding force field. This technique decreases 
the effect of long-range Coulombic interactions between charged groups.5 
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Figure 2. Bihelix methodology. (A) In Bihelix, helix rotations are sampled two at a time 
for the (B) 12 GPCR nearest neighbor pairs.5 
 
 
SuperBihelix/SuperCombihelix   
 The SuperBihelix methodology samples the helix angles θ=-10/0/10, φ=-30/-
15/0/15/30, and η=-30/-15/0/15/30 of the structure generated in the previous 
Bihelix/Combihelix step. This leads to the sampling of (3x5x5)7 or ~13 trillion structures. 
To reduce computational time, the seven-helix bundle is further partitioned into four 
QuadHelix bundles (Figure 3). A more detailed description of the energy scoring and 
approximations used can be found in our 2014 paper on SuperBihelix, along with 
validations of the methodology.5 Once again the top 2,000 of those structures are built 
and optimized via SuperCombihelix, a procedure that follows the same steps as 
Combihelix. The best structures from SuperCombihelix are then used for ligand docking. 
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Figure 3. Scoring complexes in Superbihelix. To efficiently determine a subset of 
conformations for each helix most likely to lead to the lowest energy bundles, we 
partition the seven-helix bundle into three QuadHelix bundles: TM1-TM2-TM3-TM7, 
TM2-TM3-TM4-TM5, and TM3-TM5-TM6-TM7.5 
 
 
Small Molecule Docking and Full Structure Optimization 
 After an ensemble of low-lying structures is generated for the GPCR of interest 
via GeNSeMBLE, a small molecule binding site is generated and the entire structure is 
optimized. This consists of several steps, as outlined in Figure 4. Spheres are generated 
for the GEnSeMBLE structures, ligands are generated, the ligands are docked to the 
GEnSeMBLE structures in GenDock, and the final structures undergo full-atom 
molecular dynamics. This procedure has been successfully utilized and validated against 
experimental ligand binding information in many studies.17-21 It is important to note that 
no experimental data is utilized in this procedure, and as such it is well-suited for the 
predictions of poorly understood GPCR binding sites. 
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Figure 4. GPCR small molecule binding site generation and full structure 
optimization procedure overview.  
 
Ligand Preparation 
 To obtain a small molecule ligand structure, we generate the ligand 
using Schrödinger’s ligand building suite12, 22-23. The ligand is assigned Mulliken charges 
from quantum mechanics: DFT with the B3LYP functional and the 6-31G** basis set 
using Schrödinger’s Jaguar23. Because GenDock is a rigid docking program, we generate 
a series of ligand conformations using Schrödinger’s MacroModel12: torsional sampling 
of the rotatable bonds in 30° increments. Ligand conformations are saved which are 
within 10kJ/mol of the lowest energy conformation. The conformational search is 
performed with the OPLS force field24 in a dielectric of 80 to match that of water. 
Clustering of ligands generated is performed using Schrödinger’s LigPrep22 in two 
rounds: first at 2Å diversity, followed by clustering at a 1Å diversity. Each ligand 
conformation is then minimized. 
 
Sphere Generation 
 The active site of the GPCR is defined via Dock6’s25 sphere generation tools, with 
sphere regions with a width of 10, overlap of 2, and cutoff of 75. Spheres located outside 
of the protein are eliminated. 
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GenDock 
a. DarwinDock 
Before DarwinDock, all bulky, nonpolar, residues (isoleucine, phenylalanine, leucine, 
tyrosine, valine, and tryptophan) within 4Å of the spheres are mutated to alanine using 
SCREAM. DarwinDock generates a large number of poses (5,000) using Dock6 and 
clusters them into families using Voronoi clustering at 2Å diversity. Poses are discarded 
if they clash into receptor residues more than a specified number of times depending on 
the size of the ligand. New ligand poses are added until completeness is achieved. 
Completeness is defined as when the number of new families created is less than 2% of 
the number of existing families, indicating that the binding site has been thoroughly 
sampled. A representative pose for each family is determined (the family head). The top 
10% of the family heads and members are scored, and the top 150 structures are passed 
onto the next step. The DarwinDock procedure allows for a diverse number of poses to be 
sampled, at minimal computational cost. 
b. SCREAM 
After DarwinDock, the poses are refined. First, the bulky nonpolar residues are 
restored to their wild type residues and optimized via SCREAM. The entire complex is 
then minimized for 10 steps. 
c. Neutralize 
To reduce the effect of long-range Columbic forces, charged residues are neutralized 
as described above in the Combihelix section. The same neutralization scheme is applied 
to the ligand as well, if it is charged at physiological pH. 
d. ComplexMinimize 
All atoms within 4Å of the ligand are then minimized for 50 steps or to an RMS force 
of 0.5kcal/mol/Å.  
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e. Scoring 
Snap binding energies and unified cavity energies are calculated. Snap binding energy 
is the energy difference between the complex and the sum of the receptor and ligand 
energies. Unified cavity energy is the energy between the ligand the residues in the 
unified binding site, i.e. the energies of all of the residues in all of the poses’ binding sites 
are scored for each pose. The top poses are selected based on their energies for 
undergoing molecular dynamics.  
 
Molecular Dynamics 
The full protein and ligand are then relaxed via molecular dynamics. Before 
undergoing molecular dynamics the intracellular and extracellular loops, N-terminus, and 
C-terminus of the GPCR must be constructed. This is done via homology modeling to the 
most closely related GPCR crystal structure. 
The complex is inserted into a periodic membrane and water box sufficiently 
sized to leave a minimum 15Å gap between the protein and edge of the box using 
NAMD26, with overlapping species removed. Counterions are added using NAMD. The 
water, lipids, ions, and any newly added residues are minimized for 0.5ns followed by 
equilibration at 310K for 0.5ns, and then the entire system is minimized for 0.5ns and 
equilibrated for at least 10ns, with CHARMM22 charges for the protein and 
CHARMM27 charges for the lipids27-28. Equilibration is performed in the isothermal-
isobaric (NPT) ensemble using the Nosé-Hoover Langevin piston method26, 29. The 
waters are modeled using the TIP3P potential function30. Snapshots of the equilibrated 
dimers (neglecting the first 5ns of the full system equilibration) are taken every half 
nanosecond, and minimized in the Dreiding forcefield. The lowest energy snapshots are 
analyzed. 
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Abstract 
 The glucagon-like peptide 1 receptor (GLP1R) is a G protein-coupled receptor 
involved in insulin synthesis and regulation, and therefore is an important drug target for 
the treatment of diabetes. However, GLP1R is a member of the class B1 family of 
GPCRs, for which there are no complete crystal structures (i.e. transmembrane region, 
large structured N-terminus, and peptide ligand). To provide a structural basis for drug 
design and to probe class B1 GPCR activation, we predicted the transmembrane bundle 
structure of GLP1R bound to the peptide Exendin-4 (Exe4) (a GLP1R agonist on the 
market for treating diabetes) using the MembStruk method for scanning TM bundle 
conformations. We then used protein-protein docking methods to combine the TM bundle 
with the x-ray crystal structure of the 143 amino acid N-terminus coupled to the Exe4 
peptide. This complex was subjected to 28ns of full-solvent full-lipid molecular 
dynamics. We find a total of fourteen strong polar interactions of Exe4 with GLP1R, of 
which eight are in the TM bundle (two confirmed by mutation studies) and six involve 
the N-terminus (three found in the crystal structure). We also find ten important 
hydrophobic interactions, of which four are in the TM bundle (two confirmed by 
mutation studies), and six are in the N-terminus (all present in the crystal structure). 
Thus, our predicted structure is in excellent agreement with available mutagenesis 
studies. We suggest a number of new mutation experiments for further validation of our 
predicted structure. The structure should be useful for guiding drug design and can 
provide a structural basis for understanding ligand binding and receptor activation of 
GLP1R and other class B1 GPCRs. 
 
Introduction 
The glucagon-like peptide 1 receptor (GLP1R) is a GPCR which belongs to the class 
B1 (secretin-like) family of GPCRs. Class B1 GPCRs are activated by peptide hormones. 
A feature distinguishing them from class A GPCRs is their large, highly structured, N-
terminal ectodomain, which binds their ligands. Mechanisms for class B1 GPCR agonist 
binding and activation initiation have been speculated upon 1-3, but in the absence of 
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atomic level structures of the full receptor-peptide ligand complexes it is difficult to 
understand, probe, and expand upon these activation hypotheses. 
The large ectodomain of GLP1R interacts strongly with the C-terminal half of its 
endogenous polypeptide agonist (in this case GLP1). The N-terminus of the ligand binds 
to the TM bundle and extracellular loops. Activation of GLP1R by GLP1 stimulates the 
adenylyl cyclase pathway which increases insulin synthesis and release of insulin in a 
glucose-dependent fashion 4. In addition, GLP1 reduces body weight by increasing 
satiety in the brain 5. Consequently GLP1 would seem to be attractive for treating both 
type 2 diabetes and obesity. However, GLP1 is rapidly degraded by the serine protease 
dipeptidyl peptidase-IV, resulting in a half-life of only 1-2 minutes 6-7. Exendin-4 (Exe4), 
a 39-amino acid peptide isolated from the venom of the Gila monster, is a more stable 
analog of GLP1 with a half-life of 2.5 hours in its marketed form 8-9. It has a 50% 
sequence homology with GLP1, and is a full agonist with a stronger affinity and potency 
for GLP1R 10. Indeed, Exe4 is currently on the market for treatment of diabetes. Despite 
the success of Exe4 and its derivatives, there is still a need to develop small-molecule 
(non-peptide) orally active agonists of GLP1R. This need is furthered by recent reports of 
oncogenic side effects of Exe4 11. This process of novel drug design could be aided 
significantly if there was knowledge of the full-atom structure of the full GLP1R bound 
to Exe4, which is the motivation of the research reported here. Our structure also 
provides testable hypotheses of GLP1R activation upon ligand binding. 
In the following sections, we present the predicted structure of the full membrane-
bound GLP1R/Exe4 complex in the presence of water. The TM bundle was predicted 
using the MembStruk methodology. This bundle, which was attached to the crystal 
GLP1R N-terminus and partial Exe4, was inserted into a periodic membrane in a box of 
water and relaxed via molecular dynamics (MD) 12-13. We find that this predicted 
structure is consistent with all available mutation data, but we suggest additional 
experimental tests to validate key aspects of our structure. We believe that this structural 
information presented here should help in the development of selective active small-
molecule agonists for GLP1R and also aid in probing the activation of class B1 GPCRs.  
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Methods 
Overview 
We have been developing methods for predicting the structures of the transmembrane 
region of GPCRs since the late 1990s. The earlier methodology, denoted as MembStruk, 
focused on sequential optimization of the 7 TM helices starting from a homology 
template 12. More recently, we developed a new method, denoted as GEnSeMBLE, that 
aims at a combinatorially complete set of helix rotations and tilts14. The structure that we 
report here was built entirely using MembStruk several years ago, but had not been 
published. We applied our new GEnSeMBLE methodology to the older MembStruk 
structure, but we obtained essentially the same packing of the 7 TM helices. Therefore, 
we decided to continue with our previous structure for the 7 TM helix bundle and its 
connection to the N-terminus, but we replaced the previously homology built 
nGLP1R/Exe4 part (where nGLP1R is the N-terminus of GLP1R) with the crystal 
structure which appeared more recently. 
A summary of the full procedure used to generate the GLP1R/Exe4 can be given in 10 
steps (the procedure through step 6 is depicted in Figure 1): 
1. The initial step in MembStruk is to use comparative hydrophobicity analysis of 
GLP1R and related GPCRs to identify the seven likely TM domains and then to 
position (x,y,z) the centers of these helices on a common plane with preselected tilts 
(θ, φ) and axis rotations (η) based on some template (in this case we used the 
predicted DP structure) 12, 15. We found that the TM bundle’s first helix started with 
residue 144, and then seventh helix ended with residue 408. 
2. This is followed by sequential optimization of each TM domain by varying η over 
360° in 30° increments and side chain optimization (SCREAM with modest 
minimization) in a sequence that considers all TM domains multiple times 16.   
3. Because of the large 143AA N-terminus of GLP1R, we originally built the structure 
for nGLP-1R from homology to the NMR structure of the mouse CRF receptor (PDB 
ID:2JND). This 131AA region then underwent optimization of the side chains 17. 
4. We used the ZDOCK procedure to dock the NMR structure of the full Exe4 ligand 
(PDB ID: 1JRJ) to the nGLP1R structure from step 3 18-19. 
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5. We manually docked the nGLP1R/Exe4 complex from step 4 to the TM bundle in 
such a way that the N-terminus of the ligand could interact with the TM region from 
step 1. 
6. We connected the N-terminus to the TM region (residues 131 to 145) and built the 
three extracellular and three intracellular loops using MODELLER, followed by 
SCREAM to position the side changes and then energy minimization 20. 
7. Then we inserted the full GLP1R protein into a periodic membrane and water box 
(75Å×75Å×117Å), eliminating overlapping species to obtain a system with 61,119 
atoms. This was equilibrated at 300K (first the water and membrane and then all 
atoms for 20ns) using NAMD 2.6, with CHARMM22 charges for the protein and 
CHARMM27 charges for the lipids 21-23. The waters were modeled using TIP3P 24. 
8. We then extracted the 7 TM helices from this structure and applied the SuperBiHelix 
procedure of GEnSeMBLE to obtain a new 7 TM bundle. This led to essentially the 
exact MembStruk structure for GLP1R, (in addition we found a second high-scoring 
structure differing most prominently in the η for TM1 and TM7). Consequently, we 
decided to continue the MD on the already equilibrated original structure. 
9. However, in the meantime, an x-ray crystal structure had appeared for the ectodomain 
of GLP1R (nGLP1R) bound to part of Exe4 (9-39) (PDB ID: 3C5T) 13. We matched 
this to our predicted structure and reoptimized (SCREAM, minimization, and MD for 
18ns). 
10. After the 18ns of full-atom and full-solvent molecular dynamics we performed 
simulated annealing of the TM portion of the ligand binding site, and then we carried 
10 more ns of full-atom and full-solvent molecular dynamics at 300K. A 
representative snapshot of the final 10ns of MD was chosen for the discussion below.  
Experimental information was not used during any of the above steps, except that 
information known about GLP1 loop structures was used to select loops from 
MODELLER in step 6.  
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Figure 1. Creating the GLP1R/Exe4 bundle. The steps used to create our GLP1R/Exe4 
structure are depicted, along with the methods used at each point. After the steps shown 
here, the entire complex was optimized through 28ns of molecular dynamics. 
 
Details 
 
Unless specified otherwise all minimizations referenced were conjugate-gradient 
minimizations performed in MPSim under the Dreiding forcefield (FF) 25-26.  Likewise, 
all of the molecular dynamics were performed in NAMD 2.6, using CHARMM22 
charges for the protein and CHARMM27 charges for the lipids 21-23. The waters were 
modeled using TIP3P 24. 
 
Structure Prediction of the Transmembrane Domain 
The 3D structure of the GLP1R TM bundle was predicted using MembStruk 
(version 4.3). The details of MembStruk are described elsewhere 12. Here we outline the 
procedure, highlighting aspects relevant to GLP1R or that were additionally improved. 
 
a. Prediction of Transmembrane Regions 
The transmembrane (TM) region was predicted using the TM2nsS method 12. We 
searched for the sequences of the family B GPCRs from the UnitProtKB/Swiss-Prot 
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database 27. The 166 sequences included 76 members of the LN-TM7 and 18 members of 
the Methuselah subfamilies. Only seven sequences (belonging to the receptors for 
glucagon/glucagon-like peptide and glucose-dependent insulinotropic polypeptide) 
showed a sequence identity higher than 40%. Among the 166 sequences we took 65 
sequences with pairwise sequence identity to GLP1R of >20% to calculate the 
hydropathy analysis curve. A multiple sequence alignment was performed with ClustalW 
28, which was used as input to TM2ndS for hydrophathy analysis. In this alignment, the 
long amino terminus of the sequence was excluded. The hydrophobic center for each TM 
was determined by the position bisecting the area of each peak in the curve. In order to 
define the clear boundary of the TM regions, we carried out a second round of seven TM 
predictions where the sequence of each TM core (20 amino acids around a hydrophobic 
center) was used as a query in a BLAST search. Under a high gap penalty in the BLAST 
search, the sequences with >50% identity were identified from the set of the family B 
GPCR sequences. The final refined TM region and its hydrophobic center for each of the 
7 TM domains were determined from this second round of prediction. 
 
b. Assembly of Transmembrane Helical Bundle 
We built a canonical α-helix for each TM region and assembled these seven 
helices into a template generated from the predicted structure of human prostaglandin DP 
receptor fully equilibrated in explicit lipids and water solvent 15. As expected, all 
receptors available from our family A GPCR structural database were distant in sequence 
from the GLP1R. The human prostaglandin DP receptor was chosen since it was the only 
hormone receptor in our database. Here we assumed that the arrangement of TM helices 
of the GLP1R would be similar to that of the family A GPCR. The (x, y) coordinate, the 
tilt angle with respect to z-axis and the azimuthal angle needed for definition of 
arrangement of TM α-helices as shown for frog rhodopsin 29 were calculated as follows: 
the xy mid-plane and z-axis were determined by diagonalizing the matrix of the moment 
of inertia for the heavy atoms comprising the lipid bi-layers where the human 
prostaglandin DP receptor was embedded. The +z direction pointed towards the 
extracellular region. The center of the helix bundle Cα atoms was set to origin and the x-
30 
 
axis was defined as the axis from the center of the bundle to the center of helix 2. Under 
this coordinate system, the (x, y) coordinates of each helix center and the tilt/azimuthal 
angles of each helix (the helix axis was determined from the moment of inertia of Cα 
atoms) were computed for the DP receptor template. The seven hydrophobic centers for 
GLP1R were all in the x-y plane with these (x, y) coordinates and the seven helices were 
inclined accordingly. Each helix was rotated about its axis so that its hydrophobic 
moment pointed towards the membrane. 
We then carried out 200ps of molecular dynamics at 300K without solvent or 
lipid in order to allow the conformation of each individual helix to bend or kink as 
appropriate. The molecular dynamics were run in MPSim under canonical ensemble 
(NVT) conditions with the Dreiding forcefield. We selected the lowest potential energy 
snapshot after 100ps. Using this conformation, the net hydrophobic moment vector was 
calculated from the middle 15 residue around the hydrophobic center. Each helix was 
rotated so that this hydrophobic moment vector pointed away from the center of the helix 
bundle. 
Next, the orientation of the helix was further examined with energy-based 
optimization. The rotational orientation of each helix was scanned over 360° in 30° 
increments and at each orientation the side-chains were placed using the SCREAM 
program. Here we used the coarse energy scoring function that was combined with the 
penalty score derived from the hydrophobicity scale and the FF-based SCREAM energy 
function 30.  From this scanning step, we chose two orientations for TM 1, 2, 3, 4, 5, 7 
and three for TM6, leading to the 192 combinatorial orientations. These 192 
combinations were ordered by the number of inter-helical hydrogen bonds (IHHBs), 
showing a consistent orientation for TM2, 3, and 7 on the top. These structures 
consistently showed hydrogen bonds between R190 (TM2) and N240(TM3) and between 
E247(TM3) and Q394(TM7). After that, the orientation of TM1 was scanned and the best 
orientation was chosen based on the number of IHHBs. This was motivated by previous 
experimental studies reporting that inter-helical hydrogen bonding drives strong 
interactions in membrane proteins 31-32. The orientation of TM4 was selected where the 
aromatic residues were inside the bundle and well packed with the adjacent helices. TM5 
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and 6 were then scanned combinatorially and the best rotations were chosen based on the 
sidechain-sidechain hydrogen bond energy. 
The final helix bundle was subjected to conjugate gradient minimization to a 
RMS force threshold of 0.5kcal/mol/Å. Two layers of explicit lipid molecules were then 
added to the bundle and this 7-helix-lipid complex was optimized in order to achieve the 
proper packing using rigid body molecular dynamics in MPSim with the Dreiding 
forcefield for 50ps. The final equilibrated structure was then minimized to an RMS force 
threshold of 0.3kcal/mol/Å. 
 
Structure Prediction of nGLP1R/Ligand Complex 
The structures of the N-terminus of GLP1R (nGLP1R) and ligand were modeled 
separately and then combined. The details are described elsewhere 33 and we outline the 
procedure briefly. 
 
a.  Determination of the 3-D Structure for nGLP1R 
The structure of nGLP1R was determined by homology modeling with the NMR 
structure of mouse CRF receptor (PDB ID: 2JND), which consists of 19 conformations 
17. We scored these 19 structures using the potential energy in the Dreiding forcefield, 
and selected the lowest three for equilibration in a periodic box with explicit water 
solvent. The final template structure was determined by considering the energy, and 
possible conserved structural motifs among class B1 GPCRs (i.e. the salt bridge between 
Asp65 and Arg101) and the Cα RMS with the NMR structures 1. 
We used MODELLER9v1 34 to construct homology models for residues 45-130 
of nGLP1R. The alignment of sequences between the template (the mouse CRF receptor) 
and the query (nGLP1R) was determined from the multiple sequence alignment including 
seven other secretin-like family B GPCRs whose N-terminal sequences show >30% 
identity. The side chains were replaced using the SCREAM program 16 and optimized 
with 100-steps of conjugate gradient minimization. This final optimized structure was 
then equilibrated in the explicit water box. The water box was chosen to extend by ~7 Å 
beyond the solute in each direction. The whole system was then neutralized by adding 
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Na+ ions. The solvent for each system was minimized with conjugate gradients for 5000 
steps and then equilibrated for 10 ps of molecular dynamics at 310 K using the Langevin 
thermostat with a damping coefficient of 5 ps-1 with all of the coordinates of the solute 
fixed. This system was then minimized without any constraint and equilibrated for 500 ps 
at 310 K and a pressure of 1 atm (using the Langevin piston method). All simulations 
used time steps of 1 fs with electrostatic interactions computed using the Particle Mesh 
Ewald (PME) method.  
 
b.  Docking of Ligands into nGLP1R 
The NMR structure of Exe4 (PDB ID: 1JRJ) was optimized with conjugate 
gradient minimization and equilibrated for 500 ps in explicit water solvent at 310 K and a 
pressure of 1 atm using the Langevin piston method 19. We docked the optimized Exe4 
ligand into nGLP1R (residue 45-130) using ZDOCK rigid docking program 18. By 
assuming that the Exe4 would bind to a region similar to that of mouse CRF 
receptor/astressin, we filtered the initial 2000 configurations down to 131 configurations 
17. After side-chain optimization and conjugate gradient minimization, we selected the 
top five configurations based on the FF energy, each of which were then fully minimized 
to a RMS force of 0.3 kcal/mol/Å. The lowest energy configuration was equilibrated in 
explicit water solvent with a harmonic constraint of 5 kcal/(mol Å2) for the backbone 
atoms as described previously.  
 
Combination of nGLP1R/Exe4 Complex with the Transmembrane Bundle 
In order to combine our nGLP1R/ligand complex with the TM bundle, we needed 
to grow protein residues 131 to 145. We ran secondary structure predictions on these 
residues in the programs nnPredict, GORIV, HNN, SOPMA, PSIPRED, Porter, and Jpred 
35-41.  Based on secondary structure predictions (six consensus predictions among seven) 
we found that residues 137 to 145 were helical. The conformation of this segment was 
predicted by using MODELLER9v1 under helix restraint. The overall combined structure 
was built by matching the common helical parts of residue 137 to 145 in the 
nGLP1R/Exe4 complex and the TM1 region. We first generated 1,000 conformations of 
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the residues 131 to 145 and selected ones with the correct helix chirality (right-handed) 
and the helical conformation preserved (not unraveled). Then we found the 
conformations where the ligand Exe4 was located properly inside the TM pocket without 
any bumping into helices. We examined the interactions between receptor and ligand and 
chose the conformations where the ligand key residues were involved 42. We carried out 
minimization and annealing MD for the residues of the ligand contacting TM regions and 
having random coil conformation (residues 1 to 7). The energy-minimization and 
annealing molecular dynamics were run in MPSim for three cycles (50K→600K→50K 
(50K step; 1ps run for each T)). 
 
Prediction of Loop Structures 
The first and second extracelluar loops (EC1 and EC2) were first modeled by 
using MODELLER9v1. EC1 and EC2 were 29 and 14 amino acids long, respectively. 
According to the secondary structure predictions from APSSP2 and PSIPRED servers, 
EC1 was found to be helical from residues 215 to 224 39, 43. We generated 1000 
conformations under helix restraint in MODELLER9v1 for EC1 and EC2. The restraints 
included both a distance restraint between Y205 on EC1 and F6 of the Exe4 liganda, as 
well as a disulphide bond between EC1 (residue 226) and EC2 (residue 296) 44-46. We 
chose the conformations where the predicted parts were helical and right-handed (723 
among 1000 conformations). The final three candidates were selected, for which the 
conformation was compact and not touching the presumed lipid regions, and the key 
residues of the EC1 and the ligand showed the favorable contacts (or at least close). The 
contacts emphasized were with M204, Y205, D215, and R2271 47-48.  The loops were 
optimized by side-chain replacement with SCREAM, energy-minimization of the EC1 
and EC2 only, and then three-cycle annealing MD (50K→600K→50K (50K step; 1ps 
run for each T)) in MPSim. Based on the potential energy and maximizing the total 
number of contacts, the best structure of EC1 and EC2 was chosen. Next, the 10 amino 
acid EC3 loop was modeled. Among the 1000 conformations generated from 
MODELLER9v1 we chose two candidates where the loop was not touching the presumed 
                                                          
a Since we were building both GLP1 and Exe4 in this process, and no corresponding data existed for Exe4, 
we used information from studies which were performed on GLP1.  
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lipid regions and was likely to contact T7 of the ligand that was known as one of key 
residues 45. 
The remaining three intracellular (IC) loops were modeled all together. The 
lengths of the IC1, IC2, and IC3 loops were 5, 9, and 16 amino acids, respectively. 200 
conformations were generated and the loops were chosen which sat in a closed 
conformation on top of the TM Region. The EC3 and IC loops were optimized together 
through SCREAM, energy minimization, and three-cycle annealing  molecular dynamics 
(50K→600K→50K (50K step; 1ps run for each T)) in MPSim. Based on the potential 
energy and maximizing contacts, the final structure was chosen. 
 
 Relaxation in Explicit Membrane and Water Solvent 
After predicting the full structure of the GLP1R/Exe4 complex, we embedded this 
structure in a periodic infinite membrane and solvated the system with explicit water and 
equilibrated with MD at 310K. The system size was 75Å×75Å×117Å with 6493 solute 
atoms, 5092 lipid atoms, 40302 water atoms, and 5 Na+ ions. We used palmitoyl-oleoyl-
phosphatidylcholine (POPC) to form the lipid bilayers. We made the receptor with the 
acetylated N-terminus and the N-Methylamide C-terminus. Prior to full equilibration, the 
solvent molecules were equilibrated first at 310K for 100ps, then the whole system was 
equilibrated by gradually increasing the temperature to 100K, 200K, and 310K with a 
500ps MD run performed at each temperature. Finally, the full MD simulation was 
carried out for 20ns while a constant pressure of 1 atm was maintained by using the 
Langevin piston method.  
 
Incorporating the Crystal Structure 
After the 2008 crystal structure of the human nGLP1R in complex with the 
antagonist Exe4(9-39) was revealed (PDB ID: 3C5T), we incorporated it into our GLP1R 
model 13. This crystal structure was aligned to our relaxed GLP1R bound to Exe4 
structure using VMD’s RMSD Trajectory Tool 49. This alignment was done by the 
backbone atoms of those ligand residues which were well resolved in the crystal structure 
-- 9-33. The resolved crystal residues (9-33 for Exe4 and 28-131 for GLP1R) were then 
substituted for those in our structure. Five residues on either side of the newly connected 
35 
 
residues were minimized to 0.5RMS force with conjugate gradient minimization in 
MPSim with Dreiding forcefield. Then, the entire complex was minimized to 0.5RMS 
force. This procedure allowed us to retain our TM bundle conformation and binding site, 
while adding in the crystal information. 
 
Optimizing the New Structure 
a.  Molecular Dynamics 
To optimize our models further, we ran full-lipid and full-solvent molecular 
dynamics. Each complex was inserted into a fully equilibrated hydrated POPC lipid 
blayer having a cell size of 75Å x 75Å. All lipids within 1Å and all waters within 5Å 
were removed. The complex was then solvated using the solvate package of VMD 49.  In 
order to have a net charge of zero, three sodium atoms were added to the Exe4 structure 
using the autoionize feature of VMD 49. Both structures then underwent 250ps, with a 1fs 
timestep, of conjugate gradient minimization. This was done with the protein and ligand 
kept fixed. These remained fixed as the systems were heated to 310K and equilibrated for 
500ps under NPT conditions.  Next, both entire systems were minimized for 250ps. 
Finally, the structures underwent NPT dynamics for 18ns. 
 
b.  Simulated Annealing 
Upon inspecting the dynamics runs, it was decided to optimize the transmembrane 
region binding sites further by simulated annealing in MPSim with the Dreiding 
forcefield. The proteins and ligands were taken from their MD runs, and everything 
within 5Å of the ligand was allowed to be flexible, along with the loops. These structures 
underwent minimization to 0.5RMS, with a maximum of 1000 steps, and were then 
heated from 50 to 600K in 50 degree increments, with 0.1ps (100 steps) spent at each 
temperature five times. The final structure was again minimized to 0.5RMS.  
 
c.  More Molecular Dynamics  
After annealing, the two structures were reinserted into membranes, and the above 
procedure for starting NPT molecular dynamics was repeated for 10ns. The trajectories 
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were analyzed at 1ns intervals, with each protein complex being minimized to 0.5 RMS 
force using MPSim with the Dreiding forcefield.  A representative snapshot was chosen 
for each run for discussion here. 
 
Utilizing Updated Methods on the Membstruk TM Bundle 
 With the goal of optimizing our MembStruk TM bundle, which had been through 
around twenty nanoseconds of MD, we ran Bihelix/Combihelix on the TM region 50. This 
sampled the eta angles from 0 to 360 in 30 degree increments. The top ten helix 
orientations are shown in Table 1. You can see that the all zero structure (our starting 
MembStruk structure) shows up as number nine. We then ran 
Superbihelix/Supercombihelix on all 10 of these structures, with the top two results 
shown in Table 2 51. We sampled both the eta and phi angles of each of the 10 structures 
from -30 to 30 in 15 degree increments. As you can see, the second structure is almost 
identical to the starting structure, with only two -15 degree changes to phi for helices two 
and four. Because this was so close to our starting structure, we decided to continue with 
the MD-relaxed structure for further work. The number one case, which deviates more 
from the all-zero, is not discussed in this work. 
 
Table 1. Top ten Bihelix/Combihelix structures for GLP1R 
Eta 
H1 H2 H3 H4 H5 H6 H7 
90 0 0 0 0 0 270 
0 0 0 0 0 0 270 
30 0 0 0 0 0 270 
0 0 0 0 0 30 0 
30 0 0 0 0 0 0 
0 0 0 0 270 0 0 
90 0 0 0 0 0 0 
270 0 0 0 0 0 270 
0 0 0 0 0 0 0 
240 0 0 0 0 0 270 
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Table 2. Top two Superbihelix/Supercombihelix structures 
Phi Eta 
H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 
-15 -30 0 0 0 0 15 75 15 0 0 0 15 240 
0 -15 0 -15 0 0 0 0 0 0 0 0 0 0 
 
 
Results and Discussion 
Intra-Protein Interactions 
For class A GPCRs, several conserved interhelical interactions, such as the TMs 1-2-
7 or TMs 2-3-4 hydrogen bond networks, are present in most crystal structures. The 
amino acids involved in the TMs 1-2-7 and TMs 2-3-4 interactions are not conserved in 
class the B GPCRs. However, we do find many interhelical interactions, some of which 
occur between residues conserved in class B1 which as such could be important in all of 
the class B1 GPCRs. The GLP1R/Exe4 complex has 16 hydrogen bonds within its TM 
bundle or connecting loops, as shown in Table 3 and discussed in the following sections. 
The TM-bundle interactions are pictured in Figure 2. 
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Table 3. Interhelical hydrogen bonds for the GLP1R/Exe4 structure.  
Donor Acceptor Energy 
TM3-TM6 Ionic Lock 
R348(IC3) E247(TM3) -45.4 
Coupling of TM2-TM3-TM6 
N182(TM2) E247(TM3) -10.7 
R190(TM2) N240(TM3) -15.1 
TM1-TM2-TM7 Interaction Network 
R176(TM2) E408(TM7) -52.9 
Y152(TM1) Q394(TM7) -4.7 
T149(TM1) E387(TM7) -8.1 
H180(TM2) S163(TM1) -3.5 
Extracellular Loop Couplings 
R299(EC2) D222(EC1) -46.2 
W297(EC2) D222(EC1) -6.1 
C296(EC2) D222(EC1) -5.5 
H374(EC3) M303(EC2) -6.4 
We did not include here interactions between residues within the same TM or between a TM and its 
adjoining loop. Energies are in kcal/mol. Red lettering indicates that the residue is fully conserved among 
class B1 GPCRs, green indicates that it is partially conserved, and blue means that it is conserved among 
some class B1 GPCRs. 
 
 TM3-TM6 Ionic Lock 
We consider that the conserved E247(TM3)-R348(TM6) ionic lock is analogous to 
the R(3.50)-D/E(6.30) ionic lock of class A GPRCs known to stabilize the GPCR in an 
inactive form, even though this donor and acceptor residues are swapped in the class B1 
variation of the TM3-TM6 ionic lock 52. We find this ionic lock to be maintained 
throughout the dynamics, except for a brief break 1ns break. We suggest that this 
interaction plays the role of maintaining the inactive form of class B1 GPCRs. Indeed, 
E247 is fully conserved among class B1 GPCRs, while R348 is either an R or K in all 
class B1 GPCRs. This hypothesis could be tested by mutations that break the ionic lock, 
which should lead to increased constitutive activity (GLP1R does not exhibit constitutive 
activity) 53. Although we assert that such mutations should be formed, we recognize that 
for the GLP1 system, Heller et al. studied R348G and found no activation for all 
concentrations of GLP1, while Takhar et al. found R348A to have no effect on binding or 
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activation of GLP1 54-55. Perhaps these large changes to alanine or glycine led to a 
modified TM bundle that changed the binding site. A more subtle R348Q mutation would 
test the intricacies of this ionic lock in more detail. It is also possible that this ionic lock 
is specific to the GLP1R/Exe4 complex, and is involved in its activation, but not those of 
the entire class B1 family. 
Since the TM3-TM6 ionic lock is present in our structure, it is possible that our 
complex is not yet fully activated. However our structure is bound to an agonist, and 
TM6 makes almost no interactions other than the ionic lock. Thus, it may be at least 
partially activated. This lack of TM6 interactions would allow TM6 to immediately move 
to interact with the Gα as it does in the other active GPCR structures.  
 
 Coupling of TM2-TM3-TM6 
The 3-6 ionic lock is additionally coupled to TM2 via the conserved N182(TM2)-
E247(TM3) hydrogen bond, resulting in a TM2-TM3-TM6 (2-3-6) hydrogen bond 
network [N182(TM2)-E247(TM3)-R348(TM6)]. This N182(TM2)-E247(TM3) has only 
minor fluctuations through the course of the dynamics. Since N182 is either an N, H, or 
Q in class B1 GPCRs, this 2-3-6 hydrogen bond network may occur in any of the class 
B1 GPCRs. The 2-3-6 conserved network may be further stabilized by the similarly 
conserved R190(TM2)-N240(TM3) hydrogen bond and which is shown in conjunction 
with the 2-3-6 network in Figure 2. We suggest that this interaction might be analogous 
to the TM2.45(S/N/T)-3.42(S/N/T)-4.50(W) conserved interaction of class A GPCRs, 
which are also related to their 3-6 ionic lock. Indeed, N240(TM3) is just seven amino 
acids away from E247(TM3), compared to the 3.42 just eight amino acids away from 
3.50. We find the R190(TM2)-N240(TM3) to be very constantly maintained throughout 
the dynamics. N240 is fully conserved among class B1 GPCRs while R190 is R, K, or N 
in all class B1s, so this interaction is possible in any class B1 GPCR, and therefore may 
be a feature of the class at large.  
 
TM1-TM2-TM7 Interaction Network 
The remaining two strong and conserved interactions between TM1 and TM7 
[Y152(TM1)-Q394(TM7)] and TM2 and TM7 [R176(TM2)-E408(TM7)] might play an 
40 
 
analogous role to the TM1.50(N)-TM2.50(D)-TM7.49(N)  interactions conserved among 
class A GPCRs. Perhaps it is important to keep the TM1-TM2-TM7 (1-2-7) region rigid 
to control activation. Both interactions are stable in the MD. These residues are also 
conserved in class B1 GPCRs: Y152 may be a Y or H, while Q394 may be a Q or H. 
R176 and E408 are fully conserved in all class B1 GPCRs. Note that the R176(TM2)-
E408(TM7) interactions are located in the intracellular end of the TMs, and as such could 
also play a role in G protein coupling.  
We find two additional interactions in the 1-2-7 region which involve non-conserved 
amino acids – T149(TM1)-E387(TM7) and H180(TM2)-S163(TM1) –  which further 
stabilize the 1-2-7 coupling. We find that the T149(TM1)-E387(TM7) interaction is only 
transient during dynamics, being often mediated by the H1 of the ligand. Perhaps the 
agonist will eventually break this interaction as part of activation. The H180(TM2)-
S163(TM1) interaction forms/breaks/reforms several times during the course of the 
dynamics indicating that it is less stable than the hydrogen bonds discussed previously. 
Despite their transience, these hydrogen bonds do help stabilize the coupling of the 1-2-7 
helices, and in conjunction with the  more stable conserved interactions discussed earlier, 
form a solid grouping of TMs 1, 2, and 7. The two conserved interactions, along with 
these two nonconserved interactions, are pictured in Figure 2.  
 
Extracellular Loop Couplings and N-terminal Interactions 
The remaining four interhelical interactions are between the extracellular loops. The 
first three are with D222(EC1) and adjoining EC2 residues R299, W297, and C296. In 
addition, there is a helical region present in EC1, from residue 215 to 225. It is the base 
of this helix which interacts with EC2. The final inter-loop hydrogen bond is between 
H374(EC3) and M303(EC2). The extracellular loops are clearly closely coupled, and 
provide order to the flexible loop regions, as have been seen in other GPCR crystal 
structures56. These stabilizing interactions would play a role in peptide binding, since 
they need to accommodate a peptide reaching from the N-terminus, past EC1, and into 
the TM bundle interior. Finally, GLPR1 also has the TM3-EC2 disulfide coupling (C296-
C226) conserved among class A GPCRs and among class B1. There are no other Cys in 
the EC loops. 
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The overall architecture of the N-terminus from the crystal structure remains stable 
during the course of MD. There are still the three conserved disulphide bonds, two 
regions of antiparallel β-sheets, and an alpha helix adjacent to the ligand such as occurs in 
all of the class B1 GPCR N-terminal crystal structures 57. No significant deviations from 
the crystal are observed.   
Overall, our study of GLP1R shows that there are several conserved hydrogen bond 
networks which mimic those of class A GPCRs. The 3-6 ionic lock is similar to those of 
class A GPCRs, as well as 1-2 and 2-7 networks which mimic the 1-2-7 class A motif. 
Finally, the loop structures, which may have direct bearing on ligand binding, are 
stabilized by several inter-loop interactions.  
 
 
Figure 2. The (A) TM2-TM3-TM6 and (B) TM1-TM2-TM7 conserved hydrogen 
bond networks. (A) We believe that the E247(TM3)-R348(TM6) ionic lock may be 
associated with the unactivated GPCR structure (analogous to the R3.50-D/E6.30 
interaction in class A GPCRs). TM3 is additionally coupled to TM2 via the conserved 
N182(TM2), to form a 2-3-6 interaction. This interaction is further stabilized by the 
R190(TM2)-N240(TM3) hydrogen bond, which may be analogous to the 
TM2.45(S/N/T)-3.42(S/N/T)-4.50(W) conserved interaction of class A GPCRs. (B) We 
also see several more transient couplings between TMs 1, 2, and 7 as shown here. These 
four interactions help solidify the local structure of TMs 1, 2, and 7 and their disruption 
may be involved in activation. 
42 
 
 
 
Protein-Ligand Interactions 
The GLP1R/Exe4 binding site involves interactions throughout the N-terminus, TM 
regions, and extracellular loops with the primary interactions occurring with the N-
terminus, TM1, TM2, TM7, and EC1 (see Figure 3). We find Exendin-4 to be helical 
from residues nine through twenty-nine. The strongest interactions with the N-terminus 
include six polar interactions (three which were present in the crystal structure) and six 
hydrophobic interactions (all present in the crystal structure). The TM bundle features 
eight polar interactions (two which were confirmed by mutation studies) and four 
hydrophobic interactions (two which were confirmed by mutation studies). The full 
cavity analysis for these interactions is shown in Table 6. We will discuss the binding 
site in two parts – hydrogen bonds and nonpolar interactions – and then the comparison 
to mutation data will be made in more detail. 
 
 
Figure 3. Overview of the ligand binding site’s (A) hydrophobic and (B) hydrophilic 
interactions. GLP1R is shown with a color transition from black to white as the protein 
goes from the N-terminus to the C-terminus. Exendin-4 is shown in red. Hydrophilic 
interactions are shown in panel (A), with protein residues in blue and ligand residues in 
turquoise. Hydrophobic interactions are shown in panel (B), with protein residues in 
green, and ligand residues in yellow. 
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 Polar Interactions    
We find fourteen polar interactions (hydrogen bonds or salt bridges) between GLP1R 
and Exendin-4, as listed in Table 4 and pictured in Figure 4.  For the full unified cavity 
analysis of GLP1R/Exe4, please see S3. There eight polar interactions within the TM 
region, which reflect the primary areas of interaction between the ligand and TM bundle: 
TMs 1, 2, and 7, as well as EC1. The TM-region polar interactions are particularly 
focused at the first few residues of the ligand – specifically H1 and E3, but also with T5 
and F6. Our TM-bundle interactions are further validated by site-directed mutagenesis 
studies for residues T149, E387, T391, and K197, which we find to interact with H1 and 
E3 of the ligand 58-59 as shown in Table 4. 
Our five N-terminal interactions include the two crystal salt bridges: E128(N)-R20, 
E127(N)-K27 13. These two residues’ importance has also been shown through mutation 
studies on E127 and E128 60. In addition, we find three novel very strong interactions of 
the N-terminus, of which two are in the flexible region between the structured N-terminus 
and TM1, with the other at the C-terminus of the ligand. The remaining crystal hydrogen 
bond between R121(N) and the backbone of K27 alternates during the MD between a 
water-mediated interaction and a very weak hydrogen bond.  This weak interaction is 
confirmed by the Underwood study, who found that mutating R121 to alanine (R121A) 
decreased ligand binding by only 1.6-fold 61.  
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Table 4. Polar interactions between GLP1R and Exendin-4 
GLP1R 
Residue Location 
Exe4 
Residue Energy Mutation Binding Effect 
Transmembrane Region Interactions 
T149 TM1 H1 -1.0 T149M 58 5.0 - fold reduction 
E387 TM7 H1 -6.2 E387A 60 3.9 - fold reduction 
T391 TM7 H1 -2.8 T391A 60 2.8 - fold reduction 
K197 TM2 E3 -39.6 K197A 60 3.0 - fold reduction 
K383 TM7 E3 -37.9   
Q211 EC1 T5 (backbone) -1.0   
Q210 EC1 F6 (backbone) -3.1   
K202 EC1 E17 -48.8   
N-terminal Interactions 
R134 N E16 -47.6   
E128 N R20 -44.8 E128A 13 2.4 - fold reduction * 
E139 N K12 -38.4   
E127 N K27 -33.4 E127A 13 6.8 - fold reduction * 
R40 N S39 -23.3   
Energies are given in kcal/mol and are provided to show relative strength of the interactions.  
* - Present in the crystal structure of nGLP1R/Exe4 
 
 
 
Figure 4. Exe4 hydrogen bonds with the (A) N-terminus and (B) transmembrane 
region of GLP1R. All of the receptor-ligand hydrogen bonds are depicted here and 
quantified in S3. Protein residues are shown in blue and CPK drawing method while 
ligand residues are shown in red and licorice drawing method. We find a total of fourteen 
important polar interactions of Exe4 with GLP1R of which six involve the (A) N-
terminus (including three found in the x-ray crystal structure) and eight are in the (B) TM 
bundle or loops (two of which have been confirmed by mutation studies). 
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 Hydrophobic Interactions  
 We predict 21 strong hydrophobic interactions between GLP1R and Exendin4. The 
ten strongest (cutoff of -3kcal/mol for the VDW energy) are shown below in Table 5 and 
Figure 5. We find two main clusters of hydrophobic interactions. 
 The first cluster of hydrophobic interactions occurs in EC1. GLP1R residues 
W203, M204, Y205, A209, W214, and L217 interact with Exe4 residues L10 and M14. 
Indeed, experiments on residues M204A/Y205A found a 2.7-fold decrease in binding of 
Exe4 47. We find that M204 has a -7.0kcal/mol interaction energy with Exe4, while the 
interaction energy with Y205 is -2.6kcal/mol.  
The second cluster of hydrophobic interactions occurs on one face of the helical 
portion of Exe4, interacting with the hydrophobic face of a helix of GLP1R in the N-
terminus. These include the interactions between GLP1R residues L32, T35, V36, W39, 
Y69, Y88, L89, P90, W91, and L123 with Exe4 residues V18, V19, F22, L23, L26, P31, 
and P36. These interactions include some of the strongest hydrophobic interactions in our 
entire structure: L32 at -8.4kcal/mol, W39 at -6.6kcal/mol, P90 at -4.2kcal/mol, and W91 
at -4.0kcal/mol. These interactions were all present in the crystal structure of 
nGLP1R/Exe4, and have been confirmed by mutation studies 13, 61. Specifically, the 
L32A mutation had a 7.1-fold effect on Exe4 binding and 9.5-fold on activation, while 
P90A had a 2.1-fold effect on binding and 5.5-fold effect on activation.  
We also find a final small cluster of nonpolar residues in the middle of TM3 
(L232, M233, and V229, not pictured) which form a hydrophobic pocket around G2 of 
Exendin4. These hydrophobic interactions, plus the K202-E17 salt bridge and the weaker 
polar interactions with EC1 in Table 5 (to Q210 and Q211), make it clear that EC1 is 
extremely important for Exe4 binding. 
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Table 5. Top ten hydrophobic interactions between GLP1R and Exe4. 
GLP1R 
Residue Location 
Strongest 
Interacting 
Exe4 Residue 
VDW Coulomb Hbond Total Experimental Study? 
L32 N V18, V19, F22, P36 -7.12 -1.3 0 -8.42 mutation and crystal 
W203 EC1 L10 -7.38 0.01 0 -7.37  
W214 EC1 M14 -6.33 -0.8 0 -7.13  
M204 EC1 M14 -6.64 -0.35 0 -6.99 mutation 
W39 N F22, L26, P31 -5.33 -1.3 0 -6.64 crystal 
P90 N I23 -3.25 -0.9 0 -4.15 mutation and crystal 
W91 N I23 -3.85 -0.09 0 -3.95 crystal 
Y69 N L26 -3.63 0.68 0 -2.95 mutation and crystal 
Y205 EC1 L10, M14 -3.5 0.91 0 -2.59 mutation 
Y88 N F22 -3.13 1.74 0 -1.39 mutation and crystal 
All energies are given in kcal/mol, and are summed over the GLP1R residue interactions. The residues are 
ordered by their total interaction energy. 
 
 
 
 
Figure 5. Hydrophobic interactions between GLP1R and Exendin-4 in the (A) N-
terminus and (B) extracellular loop 1 (EC1). Protein residues are shown in blue and 
CPK drawing method while ligand residues are shown in red and licorice drawing 
method. We find ten important hydrophobic interactions of which six are in the (A) N-
terminus (all confirmed by x-ray crystal structure) and four are in the (B) TM bundle 
(two of which have been confirmed by mutation studies). 
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Full Unified Cavity Analysis 
 
Table 6. Full unified cavity analysis of the GLP1R/Exe4 Binding Site. 
GLP1R Residue Location VDW Coulomb Hbond Total 
K202 EC1 4.69 -61.5 -7.98 -64.79 
K197 2 6.15 -53.75 -6.01 -53.6 
K383 7 4.41 -49.6 -5.58 -50.77 
R134 N 10.78 -49.19 -12.24 -50.65 
R40 N 3.77 -44.13 -6.39 -46.74 
R121 N -1.33 -34.39 -0.03 -35.74 
K38 N -0.25 -31.8 0 -32.05 
R190 2 2.7 -33.79 0 -31.09 
R43 N -0.44 -26.51 0 -26.95 
R227 EC1 -0.15 -26.75 0 -26.91 
K113 N -0.14 -24.39 0 -24.53 
R44 N -0.04 -24.46 0 -24.5 
K130 N -0.07 -22.17 0 -22.24 
R102 N -0.04 -20.61 0 -20.65 
R299 EC2 -0.04 -20.33 0 -20.37 
K288 4 -0.03 -20.18 0 -20.21 
R376 EC3 -0.15 -19.56 0 -19.71 
R131 N -0.02 -18.75 0 -18.78 
R380 EC3 -0.17 -17.68 0 -17.85 
R48 N -0.01 -16.68 0 -16.69 
R64 N -0.01 -14.67 0 -14.68 
R310 5 0 -12.79 0 -12.79 
R348 IC3 0 -12.56 0 -12.56 
Q210 EC1 -3.71 -4.88 -3.61 -12.19 
K351 6 0 -11.96 0 -11.96 
R170 1 0 -11.68 0 -11.68 
R176 2 0 -10.81 0 -10.81 
R326 5 0 -10.05 0 -10.05 
R267 4 0 -9.59 0 -9.59 
K346 IC3 0 -9.26 0 -9.26 
K342 IC3 0 -9.18 0 -9.18 
K334 IC3 0 -0.11 0 -9.11 
K336 IC3 0 -8.52 0 -8.52 
L32 N -7.12 -1.3 0 -8.42 
W203 EC1 -7.38 0.01 0 -7.37 
W214 EC1 -6.33 -0.8 0 -7.13 
S31 N -2.18 -4.88 0 -7.06 
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M204 EC1 -6.64 -0.35 0 -6.99 
W39 N -5.33 -1.3 0 -6.64 
H212 EC1 -4.2 -2.11 0 -6.31 
T35 N -3.06 -1.87 0 -4.92 
P90 N -3.25 -0.9 0 -4.15 
W91 N -3.85 -0.09 0 -3.95 
V36 N -2.49 -1.2 0 -3.69 
C236 3 -1.02 -2.6 0 -3.62 
Q213 EC1 -0.72 -2.89 0 -3.61 
L89 N -2.35 -1.2 0 -3.55 
Q211 EC1 -3.57 0.56 -0.49 -3.5 
T29 N -3.03 -0.41 0 -3.43 
L232 3 -2.87 -0.51 0 -3.38 
S193 2 -1.08 -2.15 0 -3.23 
T391 7 -0.61 -1.33 -1.36 -3.2 
Y69 N -3.63 0.68 0 -2.95 
Y205 EC1 -3.5 0.91 0 -2.59 
T149 1 -1.79 -0.65 -0.05 -2.49 
V229 3 -2.12 -0.2 0 -2.32 
Q37 N -0.38 -1.79 0 -2.17 
L228 3 -1.43 -0.51 0 -1.93 
L217 EC1 -1.07 -0.8 0 -1.87 
F390 7 -1.03 -0.74 0 -1.77 
A153 1 -0.43 -1.32 0 -1.76 
L384 7 -1.46 -0.29 0 -1.75 
F143 N -1.23 -0.49 0 -1.72 
S206 EC1 -1.55 -0.06 0 -1.62 
W33 N -0.83 -0.77 0 -1.6 
A209 EC1 -0.74 -0.85 0 -1.59 
L123 N -1.61 0.04 0 -1.57 
Y152 1 -0.65 -0.83 0 -1.47 
Y88 N -3.13 1.74 0 -1.39 
M233 3 -2.38 1.07 0 -1.31 
A239 3 -0.08 -1.13 0 -1.21 
Y42 N -0.16 -1 0 -1.17 
L118 N -0.15 -0.99 0 -1.15 
V194 2 -1.12 -0.02 0 -1.14 
Y235 3 -0.34 -0.77 0 -1.12 
Q221 EC1 -0.18 -0.91 0 -1.09 
E127 N -1.29 14.62 -0.65 12.69 
E139 N 5.11 16.23 -5.71 15.63 
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E128 N 11.2 16.4 -10.48 17.12 
E387 7 2.87 36.66 -5.47 17.12 
All interactions that are over -1kcal/mol, or include a hydrogen bond, are shown.  
Energies are in kcal/mol. 
 
 
Comparison to Mutation Data 
 Several mutation studies have been carried out on Exendin-4 with the intent of 
determining which residues are important for ligand binding 47, 58, 60-62. These studies are 
summarized in Table 7. Of the 26 mutations leading to a decrease in binding or activity, 
24 are consistent with our predicted equilibrium structure, while the remaining two 
appear transiently in the MD. Of these 26 residues, 13 involve the N-terminus (and were 
in the x-ray structure) while 13 involve the TM helices and EC1. 11 of the remaining 13 
residues interact with six of the seven TMs (all but TM6), plus EC1. The remaining two 
residues on TM6 (H363 and E364) are transiently involved in a hydrogen bond network 
that spans the middle of the TM bundle and extends to H1 of the ligand. Our prediction 
agrees with the conclusion of the mutation studies that D198 is not crucial for ligand 
binding 63. It is important to emphasize that the GLP1R structure (except for the N-
terminus) was derived strictly from our MembStruk method, without any use of mutation 
data (except in the loop growing, which used a distance constraint between Y205(EC1)-
F6, and required M204, Y205, D215, and R227 to be close to some part of Exe4).  
 Finally, we note that our structure preserved all interactions found in the crystal 
structure – both hydrophilic and hydrophobic – over the course of MD. This further 
validates our structure, since these interactions would be expected to be stable. In 
addition, all residues indicated in the literature to be potentially important for binding or 
activation are found in our structure to point into the TM bundle or are otherwise 
accessible to the ligand. As such they can either interact with the ligand itself or have 
structural effects. Overall, our structure strongly agrees with the available experimental 
data, making it valuable for further studies on GLP1R. 
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Table 7. Residues in the binding site with their mutation data. 
GLP1R Residue Location Experiment Ligand Interaction Type of Interaction 
L32 N L32A61, crystal13 V18, V19, F22, P36 Hydrophobic 
T35 N T35A61, crystal13 V19, F22 Hydrophobic 
V36 N V36A61, crystal13 F22 Hydrophobic 
W39 N crystal13 F22, L26, P31 Hydrophobic 
Y69 N Y69A61, crystal13 L26 Hydrophobic 
Y88 N Y88A61, crystal13 F22 Hydrophobic 
L89 N L89A61, crystal13 I23 Hydrophobic 
P90 N P90A61, crystal13 I23 Hydrophobic 
W91 N crystal13 I23 Hydrophobic 
R121 N R121A61, crystal13 K27 Hbond 
L123 N L123A61, crystal13 I23 Hydrophobic 
E127 N E127A/E127Q61, crystal13 K27 Hbond 
E128 N E128A/E128Q61, crystal13 R20 Hbond 
T149 1 T149M58 H1 Hbond 
Y152 1 Y152A60 E3 Polar 
R190 2 R190A60 E3 Polar 
K197 2 K197A60 E3 Hbond 
M204 EC1 M204A/Y205A47 M14 Hydrophobic 
Y205 EC1 M204A/Y205A47 L10, M14 Hydrophobic 
Y235 3 Y235A60 E3 Polar 
K288 4 K288A62 E3 Polar 
R310 5 R310A60 E3 Polar 
E387 7 E387A60 H1 Hbond 
T391 7 T391A60 H1 Hbond 
 
 
Testing the Predicted Binding Site 
Our predicted structure of GLP1R and its binding site with Exendin-4 suggests 
many mutation studies for testing its validity. Indeed, we constructed new structures for 
14 such mutations Q213K, S11W, R134A/Q, K202A/Q, K383A/Q, W203N/Y, and 
W214N/Y (see Table 8 for their effects on energies). The procedure was to SCREAM in 
the desired mutation, and then minimize the protein to 0.5RMS force 16. These 
calculations assumed that the overall backbone structure remains intact. Of the 14 
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mutations, two are predicted to improve binding, while 12 are predicted to decrease 
binding.  
The first set of mutations was chosen with the goal of validating our predictions 
of the strongest interactions between GLP1R and Exendin-4. Ten cases were aimed at 
disrupting the binding site by modifying protein residues: R134A/Q, K202A/Q, 
K383A/Q, W203N/Y, and W214N/Y. In each case our predicted change in binding 
agrees with expectation. The R134A/Q mutations both break the salt bridge with E16. 
The K202 mutations break the E17 salt bridge, although a weaker hydrogen bond does 
remain in the K202Q case. The K383 mutations both break the E3 hydrogen bond. The 
remaining tryptophan mutations were made with the goal of disrupting the EC1-ligand 
hydrophobic interactions. This was achieved in all of the (W203N/Y and W214N/Y) 
cases. We also suggest two ligand mutations that would decrease binding: K12A and 
M14Q. The K12A mutation would lose the E139 salt bridge, while the M14Q would 
disrupt the hydrogen bond network M14 has in the EC1 area. These predictions were 
confirmed. 
Finally, we suggest two mutations we predict to improve ligand binding. The first 
mutation was S11W of Exendin-4; which we predict allows a new interaction to be 
formed with W214. The second change is Q213K of GLP1R, which we suggest forms a 
new hydrogen bond with D9. Both of these changes improve our predicted interaction 
energies. 
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Table 8. Suggested mutations for GLP1R or Exendin-4.  
Mutation Location Motivation Change in  Interaction Energy 
Q213K Protein New Hydrogen Bond with D9 -49.4 
S11W Ligand New Hydrophobic Interaction with W214 -1.8 
WT WT WT 0 
W214Y Protein Lose M14 Hydrophobic Interaction 1.8 
W203Y Protein Lose L10 Hydrophobic Interaction 3 
M14Q Ligand Loses Hydrophobic Interactions 4.6 
W203N Protein Lose L10 Hydrophobic Interaction 4.8 
W214N Protein Lose M14 Hydrophobic Interaction 7.5 
K383Q Protein Lose E3 Hydrogen Bond 45.2 
K383A Protein Lose E3 Hydrogen Bond 57.3 
K202Q Protein Lose E17 Salt Bridge 60.2 
R134A Protein Lose E16 Salt Bridge 60.7 
R134Q Protein Lose E16 Salt Bridge 61.9 
K202A Protein Lose E17 Salt Bridge or Hydrogen Bond 68.2 
K12A Ligand Lose E139 Salt bridge 80.4 
All energies are given in kcal/mol. WT=wild type. 
 
 
Discussion of Ligand Binding and Protein Activation 
Our GLP1R/Exendin-4 structure suggests several general features of binding to 
GLP1R and potentially class B1 proteins as a whole. The first is that we find that the TM-
region polar interactions are particularly focused at the first few residues of the ligand – 
specifically H1 and E3, but also at T5 and F6. This is in accordance with the known 
importance of the N-terminus (specifically residues 1 through 7) of class B1 agonists for 
protein activation 57. In the specific case of Exendin-4, if the ligand is truncated by eight 
residues it becomes a competitive antagonist for GLP1R since it can still bind the 
receptor, but can no longer cause activation 10. 
Next, we find that Exendin-4’s binding pocket shows strong polar and hydrophobic 
interactions with EC1. Experimental studies showed that mutations of EC2 residues to 
alanine dramatically decreased binding of GLP1, but had no effect on the binding of 
Exe4 64, consistent with our structure. We suggest that the reason for the importance of 
the loops in the peptide binding is to align the ligand in the correct conformation for TM-
bundle entry. In the two-domain model of class B1 GPCR protein binding, the N-terminal 
ectodomain plays the role of recognizing the ligand and supports the initial binding 65. 
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We believe that the next step is for the flexible N-terminus/ligand complex to align itself 
to the TM bundle via loop interactions, followed by final insertion of the head region of 
the ligand into the TM bundle itself. 
Thirdly, we note that the flexible N-terminus of the ligand is nestled in the TM1-
TM2-TM7 binding pocket. This leaves the TM3-TM4-TM6 region largely open, making 
this area available for binding of small-molecules serving as ago-allosteric modulators 66. 
In addition, the residues of the ligand inserted themselves between hydrogen bonds of the 
apo GLP1R; for example, T149(TM1)-H1-E387(TM7). This suggests that part of the 
effect of Exendin-4 binding may be to break some of the TM1-TM2-TM7 strong 
interactions, giving the structure the flexibility to achieve its active conformation. 
Any discussion of GPCR activation would be incomplete without mention of the 
TM3-TM6 ionic lock, which we find a variation of in our structure. Instead of the 
conserved R(3.50)-D/E(6.30) ionic lock of class A GPRCs we find an analagous 
conserved E247(TM3)-R348(TM6) ionic lock. Breaking this interaction may be crucial 
for GLP1R activation. To test this hypothesis, one could mutate one of the charged 
residues to a polar residue such as a glutamine so that the overall hydrophilicity of the 
region could be preserved, but the interaction broken. 
Finally, it has been suggested that an N-terminal helix capping motif of a peptide 
agonist is a key element underlying class B1 GPCR activation 2. This structural feature is 
theorized to consist of a hydrophobic interaction between residues 6 and 10 and is 
stabilized by a salt bridge between residues 7 and 10 of the ligand. The result of these 
interactions is that the ligand forms an “L” at its N-terminus. While we do not see the 
exact 7-10 and 6-10 interactions – instead we find that residues Phe6 and Ser8 form a 
backbone hydrogen bond – this alternate interaction causes the ligand to adopt a slightly 
more loose “L” conformation. This structural constraint may be important for the rational 
drug design of peptide agonists targeting class B1 receptors. 
 
Conclusion 
 We present here the predicted TM bundle for GLP1R (residues 146-408) which we 
combined with the crystal structure for the N-terminus (residues 28-145). The resulting 
structure was then equilibrated in full periodic membrane and water for 28ns. This is the 
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first full-structure prediction of GLP1R bound to Exendin-4. We find strong agreement 
with available experimental data, most of which played no role in the predictions. We 
suggest 14 new mutations to provide strong tests of our predicted binding site. This 
structure can now form the basis for rational design of other peptide ligands and greatly 
needed small molecule ligands. 
The model we present here can be used to further explore the method of class B1 
GPCR binding and activation 60. In addition, we expect that this structure will provide a 
basis for design and optimization of new small-molecule ligands that bind selectively and 
specifically to GLP1R. 
Finally, one of the grand challenges in understanding GPCRs is to elucidate the 
mechanism of activation. This study does not address this issue directly; however, we do 
identify a TM3-TM6 ionic lock which is conserved across class B1 GPCRs that we 
believe may play a very similar role in activation to the TM3-TM6 ionic lock conserved 
across a subset of class A GPCRs. Mutation studies on this ionic lock will help test such 
speculations and provide structural signatures of active and inactive receptor 
conformations. 
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Abstract 
 Class B1 G protein-coupled receptors (GPCRs) are a subfamily of GPCR which 
share little to no sequence homology with the more well-characterized class A GPCRs. In 
the last year, two transmembrane region crystal structures of class B1 GPCRs have been 
obtained, that of the corticotropin-releasing factor 1 receptor (CRFR1)1 and the glucagon 
receptor (GLR)2. We use these two structures as starting points for the well-validated 
GEnSeMBLE method of structure prediction on seven novel class B1 GPCRs (CALRL, 
GIPR, GLP1R, PACR, PTH1R, VIPR1, and VIPR2), as well as the two crystallized 
proteins. An analysis of the predicted structures shows two fully conserved interactions 
across the family: R2.46-E3.50 and R/K6.37-Y/F7.57, as well as several more 
interactions present in at least half of the structures. The nine predicted structures are 
docked to small molecule ligands, revealing a consistent binding site in the center of the 
protein, between transmembrane helices 3 and 7. This binding site differs from that of 
class A GPCRs, and may be characteristic of the class B1 receptors. We propose protein 
mutation experiments to test the validity of our binding sites. Additionally, we suggest 
the characteristics of an optimal ligand for the binding site. Our work provides a strong 
starting point for drug design targeting these receptors, on top of characterizing a protein 
family with little full-atom information available. 
 
Introduction 
In the last year, two class B1 GPCRs have been crystallized – the corticotropin-
releasing factor receptor 1 (CRFR1, 3.0Å resolution)1 and the glucagon receptor (GLR, 
3.4Å resolution)2. CRFR1 was crystallized with a small molecule antagonist CP-376395. 
Likewise, GLR was crystallized with the small molecule antagonist NNC0640, but the 
ligand was not resolved in the crystal structure. In both cases, modifications were made to 
the protein to allow for crystallization to occur. For CRFR1, twelve amino acids were 
mutated and the T4 lysozyme was inserted into the intracellular loop 2.1 For GLR, the 
thermally stable E. coli apocytochrome b562RIL replaced the N-terminus of the protein.2  
The recent availability of class B1 GPCR transmembrane region crystal structures 
provides high quality starting structures for the predictions of other class B1 GPCR 
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transmembrane region structures and binding sites. We present here the GEnSeMBLE 
predicted ensemble of 3D structures of nine class B1 GPCRs, along with their binding 
sites to small molecule ligands (Table 1). Very little is known about how these ligands 
interact with their proteins so any knowledge we can obtain about binding sites is novel 
and useful in optimizing the ligands for possible drug use. 
 The nine class B1 GPCRs we will be predicting the structures of are the calcitonin 
gene-related peptide type 1 receptor (CALRL), corticotropin-releasing factor receptor 1 
(CRFR1), glucagon receptor (GLR), gastric inhibitory polypeptide receptor (GIPR), 
glucagon-like peptide-1 receptor (GLP1R), pituitary adenylate cyclase-activating 
polypeptide type I receptor (PACR), parathyroid hormone/parathyroid hormone-related 
peptide receptor (PTH1R), vasoactive intestinal polypeptide receptor 1 (VIPR1), and 
vasoactive intestinal polypeptide receptor 2 (VIPR2).a,3 These nine receptors were chosen 
based on their evolutionary diversity (Figure 1), and the fact that small molecule ligands 
were known for each receptor. We also predict the structures of the wild type CRFR1 and 
GLR which already have x-ray crystal structures for two reasons: to validate our 
methodology as well as to determine if the crystallization procedures affected the 
conformation of the GPCRs. The goal of this work is to obtain high quality 
transmembrane region and binding site predictions for nine class B1 GPCRs, to examine 
the similarities and differences in the structures and binding sites of the receptors, and to 
suggest optimizations of the nine ligands which may improve their efficacy as drug 
candidates.  
 
Table 1. The nine class B1 GPCRs and their small molecule ligands. 1-2, 4-10 
                                                          
a The abbreviation scheme used here is that of the Universal Protein Resource (UniProt). In particular, note 
that the glucagon receptor is sometimes abbreviated as GCGR and the corticotropin-releasing factor 
receptor 1 as CRF1R. 
Receptor Principal Biological Actions 
Small Molecule 
Ligand 
Calcitonin gene-related peptide 
 type 1 receptor (CALRL) Vasodilation, transmission of pain 
 
MK-0974 
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Corticotropin-releasing factor  
receptor 1(CRFR1) ACTH release, central stress response 
 
CP-376395 
Glucagon receptor 
(GLR) Regulation of blood glucose 
 
NNC0640 
Gastric inhibitory polypeptide 
 receptor (GIPR) Insulin secretion 
 
Mol 29 
Glucagon-like peptide-1 receptor 
(GLP1R) Insulin and glucagon secretion 
 
T0632 
Pituitary adenylate cyclase-activating 
polypeptide type I receptor 
(PACR) 
Neurotransmission, 
neuroendocrine functions 
 
Mol 1 
Parathyroid hormone/ 
parathyroid hormone-related  
peptide receptor 
(PTH1R) 
Ca2+ homeostasis, 
developmental regulator 
 
SW106 
Vasoactive intestinal  
polypeptide receptor 1 
(VIPR1) 
Vasodilation, neuroendocrine 
functions, neurotransmission 
 
Mol 4 
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Figure 1. Phylogenetic tree for the class B1 receptors.11 Proteins that we predicted are 
colored, red blue indicating those with x-ray crystal structures of the transmembrane 
region and red indicating the other seven GPCRs. 
 
Methods 
Structure Prediction 
A more detailed explanation of each of these steps is provided in Chapter II. 
1. Homology helix prediction – We predict helix lengths, locations, and orientations for 
each of the nine class B1 GPCRs using the two class B1 crystal structures as 
templates, resulting in eighteen starting structures. 
Vasoactive intestinal polypeptide 
receptor 2 
(VIPR2) 
Vasodilation, neuroendocrine 
functions, neurotransmission 
 
Mol 6 
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2. Bihelix - Helices are rotated in 30° increments from 0-360° (η) and the energies are 
estimated for all 127 (35 million) structures in terms of energies for each of the twelve 
pairs.12 
3. Combihelix- The top 2,000 seven-helical bundles from Bihelix are assembled and 
their energies calculated after optimizing side chains. The best template and helix 
rotations (η) are determined from the average charged and neutral interhelical 
energies, and are submitted to Superbihelix. Total energies were not used for the 
comparison due to the different TM lengths of the proteins.  
4. Superbihelix – We estimate the energies for all (3*5*5)7 (13 trillion) combinations of 
angles: θ (-10, 0, 10), φ (-30, -15, 0, 15, 30), and η (-30, -15, 0, 15, 30) of the best 
Combihelix structures, by combining Bihelix energies into sets of four.13 
5.  Supercombihelix – We assemble, optimize side chains, and score the top 2,000 
Superbihelix bundles. The top structure is selected for docking. 
 
Binding Site Prediction 
6. DarwinDock/GenDock  - The ligands from Table 1 are docked to the best structures 
from Supercombihelix. Approximately ten diverse ligand conformations are 
generated using Maestro’s MacroModel14 conformation search. Around 50,000 poses 
are generated for each using UCSF’s Dock615. The poses are clustered by CRMS, and 
the family head energies evaluated; then all of the children energies are evaluated for 
the top 10%. The best 120 poses are selected by using polar, total, and hydrophobic 
energies. These steps are performed with hydrophobic residues mutated to alanine.  
7. Scoring - The residues are dealanized, SCREAMed16, neutralized13, and minimized in 
the Dreiding17 forcefield to obtain 120 poses with optimized side chains. The final 
best poses are selected by snap binding energy. 
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Results and Discussion 
Structure Prediction 
We predicted the structures for nine class B1 GPCRs. The sequence conservation 
for the transmembrane helices is shown in Figure 2, along with the most conserved 
residue of each transmembrane region, marked as X.50. This figure illustrates the relative 
conservation of the TMs: TM2 and TM4 are the most conserved, with the prolines 
throughout the receptor being conserved as well. 
 
Figure 2. WebLogo representation of the sequence identities between the 
transmembrane regions of the nine class B1 predicted structures.18 Larger residue 
symbols indicate higher sequence identity. Polar residues are green, basic are blue, acidic 
are red, and hydrophobic are black. The red arrows indicate the X.50 residues as 
described in Siu FY, et al. 2013.2 
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Bihelix/Combihelix  
Bihelix and Combihelix were run for the nine protein structures sampling the eta 
angles from 0-360° in 30° increments. The top structures from each case are shown in 
Tables A1-A9 of the Appendix. Seven of the nine structures prefer the glucagon 
receptor template. The remaining two, CALRL and CRFR1, preferred the CRFR1 
template.  This is not surprising when looking at the relationship between the class B1 
GPCRs as shown in Figure 1 – CALRL is much more closely related to CRFR1, while 
the other receptors are more closely related to GLR. 
The structures in Table 2 were chosen as starting points for the Superbihelix fine 
sampling of θ, φ, and η (θ: -10, 0, 10 / φ: -15, 0, 15 / η: -30, 0, 30). The structures were 
selected based on these criteria: the number 1 structure was always included, as was the 
all-zero rotation. The all-zero rotation was always included based on previous 
experiences showing it to often be a strong starting point for Superbihelix.19-27  
Table 2. Summary of structures input to Superbihelix from Bihelix/Combihelix 
Protein Template Rank 
Eta (η) 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 
CALRL CRFR1 1 0 0 0 0 0 0 0 
CRFR1 CRFR1 1 0 0 0 0 0 0 0 
GLR GLR 
1 0 0 0 0 0 -30 0 
7 0 0 0 0 0 0 0 
GIPR GLR 1 0 0 0 0 0 0 0 
GLP1R GLR 
1 0 0 0 0 0 -30 0 
9 0 0 0 0 0 0 0 
PACR GLR 
1 0 0 0 0 0 30 0 
2 0 0 0 0 0 0 0 
PTH1R GLR 
1 0 0 0 150 30 -120 0 
3 0 0 0 0 0 0 0 
VIPR1 GLR 1 0 0 0 0 0 0 0 
VIPR2 GLR 1 0 0 0 0 0 0 0 
 
 
 
68 
 
Superbihelix/Supercombihelix 
 The Superbihelix/Supercombihelix top structures are shown in Tables A10-A18 
of the Appendix. The rank 1 structure in each case was used for docking. Table 3 
summarizes these results. The helices with the largest variations throughout our nine 
receptors are: TM4 (φ), TM5 (η), and TM7 (η). The Superbihelix/Supercombihelix 
structures for CRFR1 and GLR are marked by red text. The CRFR1 structure has 0.9Å 
RMSD to the CRFR1 x-ray crystal TM region and the GLR structure has 2.1Å RMSD to 
the x-ray crystal TM region. It is interesting to note that throughout our structure 
prediction procedure, the GLR structure has consistently varied more from that of the 
crystal structure than CRFR1 did. It is important to remember that GPCRs exist in several 
low-lying states. It is entirely possible that the conditions necessary to obtain crystal 
structures of GLR and CRFR1favored one of these states, while we find another. 
 
Table 3. Superbihelix/Supercombihelix results for the nine predicted structures. 
Protein 
Theta (θ) Phi (φ) Eta (η) 
H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 
CALCRL -10 0 0 0 0 0 0 15 0 0 -30 15 15 15 15 0 0 0 15 -30 -15 
CRF1R 0 0 0 0 0 0 -10 0 0 0 -15 0 15 0 0 0 0 0 0 0 15 
GCGR 0 -10 -10 0 -10 10 10 -30 0 0 -30 15 15 0 0 0 0 15 -30 -15 0 
GIPR 0 -10 -10 0 -10 0 10 -15 0 0 -30 0 15 -30 0 0 0 15 -15 0 15 
GLP1R 0 -10 -10 0 -10 0 10 0 -15 0 -15 -15 30 -15 0 0 -15 0 -15 0 15 
PACAPR 0 0 0 0 0 0 10 -15 0 0 -30 0 0 -15 0 0 0 0 15 0 15 
PTH1R 0 -10 -10 0 -10 0 10 0 -15 0 -30 -15 15 -30 15 0 -15 0 -15 -30 30 
VIPR1 -10 0 0 0 0 10 10 30 0 0 -15 0 0 -30 -15 0 0 0 15 -15 15 
VIPR2 0 -10 -10 -10 -10 0 10 0 -15 0 30 15 30 -15 15 0 0 -15 15 -15 15 
Angles are with respect to the starting template –  
CRFR1 for CALCRL and CRFR1, and GLR for the rest. 
 
 
Interhelical Interactions 
The interhelical interactions of each of the nine Superbihelix/Supercombihelix 
structures are shown below in Table 5. A summary of the conserved interactions is 
shown in Table 4 and depicted for GLR in Figure 3. All nine structures show an 
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interaction between TM2-TM3 (R2.46-E3.50) as well as an interaction between TM6 and 
TM7: R/K6.37-Y/F7.57. Six of the structures show additional interactions between TMs 
2 and 3: R2.46-Y3.53, and/or H2.50-E3.50, and five have an additional TM2-TM3 
interaction, which is weaker: N3.43-A/S2.56. Additionally, TMs 2 and 7 also interact in 
five of the structures via K/R2.60-Q7.49 and four of the structures via K/R2.60-
G/S/E/N7.46. It is important to note that in every case where one of the conserved 
interactions is not present, the residues are instead forming other interactions, thereby 
stabilizing that conformation.  From these conserved interactions, one can see that in 
class B1 GPCRs, TMs 2 and 3 are very closely coupled, with TMs 6-7 and TMs 2-7 also 
interacting tightly. We do not see the TMs 1-2-7 and TMs 2-3-4 interactions which are 
consistently present in the class A GPCRs because of the low sequence homology 
between the GPCR families. The residues involved in those class A GPCRs are not 
conserved in class B1. 
Table 4. Class B1 conserved interactions 
Protein 
TM2-TM3: TM6-7: TM2-7: 
R2.46-E3.50 R2.46-Y3.53 H2.50-E3.50 N3.43-A/S2.56 R/K6.37-Y/F7.57 K/R2.60- Q7.49 
K/R2.60-
G/S/E/N7.46 
CALRL Y N Y N Y N N 
CRFR1 Y N Y Y Y Y Y 
GLR Y Y Y Y Y Y Y 
GIPR Y Y Y Y Y N Y 
GLP1R Y Y N A (R2.60-N3.43) Y N N 
PACR Y Y Y N A (R6.37-L7.56) N N 
PTH1R Y Y N N Y Y Y 
VIPR1 Y Y Y Y Y Y N 
VIPR2 Y N N N Y Y N 
Total 9 6 6 5 9 5 4 
A=alternate 
 
70 
 
 
Figure 3. Class B1 conserved interactions, as found in the GLR predicted structure. 
(A) TM2-TM3 interactions: R2.46-E3.50, R2.46-Y3.53, H2.50-E3.50, and N3.43-
A/S2.56. (B) TM6-TM7 and TM2-TM7 interactions: R/K6.37-Y/F7.57, K/R2.60-Q7.49, 
and K/R2.60-G/S/E/NN7.46  (C) Overview of the structure showing the locations of the 
interactions. 
 
 
Table 5. Class B1 predicted structure interhelical interactions 
   KEY    
   Identical in all class B1 GPCRs    
   Conserved mutations occur in class B1 GPCRs    
   Semi-conserved mutations occur in class B1 GPCRs    
   Not conserved across the class B1 GPCRs    
   Conserved interaction    
   Crystal interaction    
   CALRL     
   1--2--7 2--3--4 Other    
   N140_1 Y367_7 R173_2 E233_3 Y227_3 E348_6    
   T145_1 H374_7 H177_2 E233_3 K319_5 E327_6    
   S159_1 S381_7 N179_2 Y256_4 K333_6 F386_7    
     K213_3 A271_4 Q376_7 E348_6    
     K213_3 S275_4      
     Y221_3 W260_4      
     R274_4 Q216_3      
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CRFR1  CRFR1 Crystal 
1--2--7 2--3--4 Other 1--2--7 2--3--4 Other 
W156_2 F138_1 R151_2 E209_3 N196_3 Y272_5 S130_1 F357_7 H155_2 E209_3 W246_4 D269_5 
R165_2 E352_7 H155_2 E209_3 H199_3 M276_5 S130_1 S353_7 N157_2 W236_4 K250_4 D269_5 
Q355_7 R165_2 R189_3 A247_4 W246_4 D269_5 R151_2 N367_7 Y197_3 W236_4 Q355_7 Y327_6 
  Y197_3 W236_4 K250_4 D269_5 N152_2 N367_7     
  N202_3 A161_2 Q308_6 L366_7       
  K228_4 N157_2 Y309_6 A216_3       
    K311_6 F365_7       
    K311_6 L366_7       
    K311_6 N367_7       
GLR  GLR Crystal 
1--2--7 2--3--4 Other 1--2--7 2--3--4 Other 
Q142_1 D195_2 R173_2 Y248_3 Y239_3 E362_6 S152_1 G393_7 R225_3 C287_4 L242_2 N318_5 
Y145_1 F383_7 R173_2 E245_3 R308_5 E362_6 T146_1 D195_2   Y239_3 L358_6 
Y149_1 S389_7 H177_2 E245_3 R308_5 A366_6 K187_2 S389_7   H361_6 Q392_7 
K187_2 Y149_1 R225_3 C287_4 N318_5 L242_3     Y400_7 T351_6 
K187_2 S389_7 N238_3 S183_2 K344_6 L329_5       
K187_2 Q392_7   K344_6 K332_5       
R199_2 Q142_1   R346_6 Y400_7       
   GIPR     
   1--2--7 2--3--4 Other    
   Y145_1 S381_7 R169_2 Y240_3 R183_2 E354_6    
   N170_2 L159_1 R169_2 E237_3 Y231_3 E354_6    
   R183_2 S381_7 H173_2 E237_3 R300_5 E377_7    
   R192_2 T142_1 S179_2 N230_3 R336_6 L241_3    
   R192_2 Q138_1 R190_2 Q220_3 R338_6 Y392_7    
     R217_3 Y279_4 T343_6 Y392_7    
     Y279_4 Q224_3 K373_7 F357_6    
       K373_7 A358_6    
       S381_7 E354_6    
   GLP1R     
   1--2--7 2--3--4 Other    
   Y152_1 T391_7 R176_2 E247_3 Y241_3 I357_6    
   N177_2 L166_1 R176_2 Y250_3 W306_5 R380_7    
     R190_2 N240_3 R310_5 E364_6    
     R190_2 V237_3 K346_6 L251_3    
     R227_3 Y289_4 R348_6 Y402_7    
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     Y235_3 V282_4 R348_6 C403_7    
     Y269_4 T253_3 T353_6 Y402_7    
       R380_7 Y305_5    
       R380_7 M303_5    
       K383_7 F367_6    
       K383_7 A368_6    
   PACR     
   1--2--7 2--3--4 Other    
   K154_1 D207_2 R185_2 E247_3 Y241_3 F362_6    
   T158_1 D207_2 R185_2 Y250_3 N320_5 L244_3    
   H189_2 Y400_7 H189_2 E247_3 Y348_6 L251_3    
   R199_2 E385_7 K227_3 L289_4 R350_6 L399_7    
   R379_7 Y150_1   T355_6 E247_3    
       Y366_6 E385_7    
       R381_7 V368_6    
       Y400_7 E247_3    
   PTH1R     
   1--2--7 2--3--4 Other    
   Y191_1 H442_7 R219_2 E302_3 Y297_3 P366_5    
   Y195_1 D241_2 R219_2 Y305_3 Y297_3 S370_5    
   N220_2 L209_1 R282_3 A344_4 K359_5 Q440_7    
   R233_2 N448_7   K359_5 E444_7    
   R233_2 Q451_7   K360_5 F424_6    
   Y245_2 D185_1   K360_5 Q440_7    
   Y459_7 H223_2   Q364_5 F424_6    
       K405_6 Y459_7    
       K408_6 I458_7    
       Y421_6 N448_7    
       Q440_7 F424_6    
   VIPR1     
   1--2--7 2--3--4 Other    
   K143_1 D196_2 R174_2 E236_3 N308_5 L233_3    
   Y146_1 D196_2 R174_2 Y239_3 R317_5 Y241_3    
   T147_1 D196_2 H178_2 E236_3 Y336_6 L240_3    
   Y150_1 G377_7 S184_2 N229_3 R338_6 Y388_7    
   R188_2 Y150_1 F185_2 N229_3 Q380_7 Y354_6    
   R188_2 Q380_7 R188_2 C225_3      
     R188_2 V226_3      
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     K216_3 I278_4      
     Y224_3 M271_4      
     S267_4 Y224_3      
   VIPR2     
   1--2--7 2--3--4 Other    
   K127_1 D180_2 R158_2 E223_3 R172_2 Y341_6    
   K127_1 D181_2 W249_4 N164_2 N295_5 F217_3    
   Y134_1 D180_2 T253_4 Y211_3 K324_6 K309_5    
   N159_2 L148_1   R325_6 Y375_7    
   R172_2 Q367_7   Y341_6 G364_7    
   Y375_7 H162_2   Q356_7 F344_6    
 
The CRFR1 predicted structures can be compared to the x-ray crystal structure of 
CRFR1. These interactions occur in both structures: H2.50-E3.50, W4.50-Y3.38 (present 
in CALRL as well), W4.60-D5.36, and K4.64-D5.36. The W4.60-D5.36 interaction may 
be present in proteins closely related to CRFR1. There are, however, six interactions of 
the crystal structure which we do not see between helices 1-7, 2-7, 2-4, and 6-7. We can 
also compare the predicted GLR structure to that of the GLR crystal structure. Both 
structures have the K/R2.60-G/S/E/N7.46 interaction, as well as R3.30-C4.65. There are 
six “missing” hydrogen bonds from the crystal structure. In both cases, the reasons for the 
absent crystal structure interactions are multifold: 1. Both crystal structures were 
modified to allow for crystallization, which may possibly affect their TM bundle 
conformations and interactions. 2. Our structures do not have loops or waters present, 
which would primarily affect the more terminal residue interactions. 3. GPCRs have 
several low energy conformations28, and it is possible that we are seeing a low-lying 
structure which differs from the one crystallization conditions favored. 
 
Binding Site Prediction 
 We predict the small molecule ligand (from Table 1) binding sites to the nine 
class B1 GPCRs.  The binding sites are consistently placed between TMs 3 and 7. Often 
TMs 2, 4, and 6 are involved as well, and much more rarely 1 and 5. This localization of 
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the small molecule ligands is similar to that which is consistently seen in the more well-
characterized class A GPCRs, but is shifted more towards the center of the TM bundle 
(Figure 4). In class A GPCRs, TMs 5 and 6 play a much larger role in the small molecule 
interactions than that which we see here.29-30 
 
Figure 4. Comparison of the class A and class B1 GPCR binding sites. (A) Side view 
and (B) top view of the β2-adrenergic receptor30 (yellow) and our predicted GLR 
structure. Note that the ligand is more centrally located in the class B1 GPCRs, while it is 
closer to TM5 in the class A GPCRs. 
 
 The predicted binding sites for the nine proteins are pictured in Figures 5-13. For 
each structure we present an overview of its location, in which the TM regions are 
colored red->white->blue as they go from 1->7. We also present the ligand’s 
pharmacophore, in which residues are colored: red - acidic, green - hydrophobic, purple - 
basic, blue - polar, and white - glycine. Finally, we present a table of the strongest 
interacting residues (note that these energies are from the neutralized complexes, and are 
therefore lower for charged residues than they would be otherwise). Because very little is 
known about these ligands’ binding sites, we are unable to fruitfully compare to 
experimental data. Instead, we use our binding site information to suggest protein 
mutation studies which could test our binding site. Additionally, we suggest the 
characteristics of ideal ligands for the binding location. 
75 
 
 For CALRL bound to MK-0974 (Figure 5), we find that the ligand interacts with 
TMs 2, 3, 5, 6, and 7. To test if our binding site is accurate, we suggest performing 
experiments to probe the importance of Glu348; for example, testing the effect of a 
Glu348Ala mutation. We note that a positively charged ligand would be ideal for 
interacting with Glu348, possibly with aromatic components to interact with His295 and 
Phe349. 
 
 
Figure 5. CALRL bound to MK-0974. (A) Predicted structure binding site 
overview. (B) Predicted structure pharmacophore. (C) Strongest interactions 
between the protein and ligand (kcal/mol). MK-0974 adopts a folded 
conformation which interacts with TMs 2, 3, 5, 6, and 7. 
 
 
For CRFR1 we can compare our structure to that of the crystallized CRFR1- CP-
376395. Our binding site is similar, but slightly shifted towards TM7 (Figure 6).  Both 
binding sites are placed low in the protein – an unusual binding site which has not been 
seen in any of the other crystallized GPCRs, and may be unique to this receptor. To 
ensure that our binding site is not an artifact of our procedure, we also docked the crystal 
ligand to the crystal protein (C and D of Figure 6). This results in a binding site nearly 
identical to that of the crystal structure. Therefore, our CRFR1 predicted structure’s 
binding site is a reflection of its structural variations and sequence differences from that 
of the crystal. It is also important to note that our structure’s binding site was also slightly 
more favorable energetically than the crystal binding pose: the crystal snap binding 
energy was -50.4 kcal/mol while our structure was -51.2 kcal/mol. To test our binding 
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site, and also its validity in comparison to the x-ray crystal structure’s, we suggest two 
mutations: His155Ala and Asn283Ala. If the first mutation has a large effect on CP-
376395 binding, it may reflect the accuracy of our prediction, if the second does then it 
would indicate that the crystal ligand binding pose is more accurate. 
 
Figure 6. CRFR1 bound to CP-376395. (A) Predicted structure binding site overview. 
(B) Predicted structure pharmacophore. (C) Strongest interactions between the predicted 
CRFR1 and CP-376395 (kcal/mol). (D) Crystal structure binding site, with our docking 
results of the crystal ligand and protein shown in orange. (E) Crystal structure 
pharmacophore. The predicted CRFR1:CP-376395 binding site interacts with TMs 2, 3, 
6, and 7, while the crystal binding site interacts with TMs 3, 5, and 6. 
 
 
 The GLR crystal structure did not have a resolved ligand, therefore no direct 
comparison can be made between the two structures. However, we docked NNC0640 to 
both our predicted GLR structure, and the crystal structure (Figure 7). The poses are 
nearly identical, despite the structural variations between the GLR predicted and crystal 
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structures. However, the predicted structure’s binding pose was more energetically 
favorable than the predicted crystal structure binding pose: a snap binding energy of  
-89.5kcal/mol versus -80.4kcal/mol for the crystal predicted pose. Our predicted pose 
may be the more physical structure for binding to NNC0640, especially since the ligand 
was not stably in complex with the crystal protein. To evaluate our binding sites we 
would suggest two mutation studies: Arg225Ala and also Phe365Ala. Depending on the 
results, one or the other binding site may be found to be more physical. To optimally 
interact with this binding site, a ligand with two negative charges could be designed 
which targets both Lys187 and Arg378 (or Arg 308). 
 
 
Figure 7. GLR bound to NNC0640. (A) Predicted structure binding site overview. (B) 
Predicted structure pharmacophore: the ligand interacts with TMs 2, 3, 5, 6, and 7. (C) 
Strongest interactions between the predicted protein and ligand (kcal/mol). (D) Predicted 
crystal structure binding site (the ligand was not resolved in the crystal structure). (E) 
Predicted crystal structure pharmacophore: the ligand interacts with TMs 2, 3, 5, 6, and 7. 
(F) Strongest interactions between the predicted crystal protein and ligand (kcal/mol). 
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 The GIPR: Molecule 29 binding pose is presented in Figure 8. Molecule 29 
interacts with TMs 1, 2, 3, 5, and 7. To test the validity of our binding site we suggest 
three mutations: Arg190Ala, Arg370Ala, and Arg278Ala. Additionally, the large number 
of positively charged residues in the binding site indicates that a drug designed with 
multiple negatively charged groups (or at least strongly polar if many negative charges 
proves to be energetically unfavorable ) that is also large enough to hit all four arginines 
would be ideal. Alternatively, a ligand with one or two negative charges could hit a 
subset of the four arginines and be less prone to poor columbic energies. 
 
 
Figure 8. GIPR bound to Molecule 29. (A) Predicted structure binding site overview.  
(B) Predicted structure pharmacophore. (C) Strongest interactions between the protein 
and ligand (kcal/mol). The rather large Molecule 29 bridges most of the protein and 
interacts with TMs 1, 2, 3, 5 and 7. 
 
 
 GLP1R bound to T0632 is shown in Figure 9. The ligand interacts with TMs 2, 3, 
5, and 7. To probe this binding site, we suggest three protein mutations: Tyr305Ala, 
Lys197Ala, and Glu387Ala. Additionally, the combination of Lys197 and Glu387 in the 
binding pocket suggests that a zwitterionic ligand may be ideal for interacting with 
GLP1R. 
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Figure 9. GLP1R bound to T0632. (A) Predicted structure binding site overview. (B) 
Predicted structure pharmacophore. (C) Strongest interactions between the protein and 
ligand (kcal/mol). T0632 orients itself vertically between TMs 2, 3, 5 and 7. 
 
 
 PACR bound to Molecule 1 is presented in Figure 10. Molecule 1 interacts with 
TMs 1, 2, 3, 6, and 7. We suggest several mutation studies to test our binding site: 
His234Ala, Tyr241Ala, Glu385Ala, and Tyr366Ala. Additionally, we note that it may be 
ideal to generate a ligand with a positive charge to interact with Glu383, and/or multiple 
aromatic and polar groups to interact with the binding pocket’s tyrosines. 
 
 
Figure 10. PACR bound to Molecule 1. (A) Predicted structure binding site overview.  
(B) Predicted structure pharmacophore. (C) Strongest interactions between the protein 
and ligand (kcal/mol). Molecule 1 is quite large, but it takes a folded conformation and 
interacts with TMs 1, 2, 3, 6, and 7. 
 
80 
 
SW106’s binding site with PTH1R is depicted in Figure 11. The ligand interacts 
with residues on TMs 2, 3, 5, 6, and 7. To test the validity of our binding site we suggest 
two mutation experiments: Arg233Ala and Gln451Ala. Additionally we note that a 
negatively charged ligand would be ideal for interacting with this binding pocket, 
possibly also with polar atoms to hit Gln451 and an aromatic group to interact with 
Phe447. 
 
Figure 11. PTH1R bound to SW106. (A) Predicted structure binding site overview. 
(B) Predicted structure pharmacophore. (C) Strongest interactions between the protein 
and ligand (kcal/mol). SW106 is small overall, and takes a binding pose relatively low in 
the protein. It interacts with TMs 2, 3, 5, 6, and 7. 
 
 
 VIPR1 bound to Molecule 4 is shown in Figure 12. The ligand interfaces with 
TMs 2, 3, 4, 5, and 7. To probe our binding site we suggest two experiments: Gln223Ala 
and Lys195Ala. To optimally interact with this binding pocket, a zwitterionic ligand 
could be explored with the intent of binding to both Lys195 and Glu373. 
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Figure 12. VIPR1 bound to Molecule 4. (A) Predicted structure binding site overview. 
(B) Predicted structure pharmacophore. C) Strongest interactions between the protein and 
ligand (kcal/mol). The small molecule 4 interacts with TMs 2, 3, 4, 5 and 7. 
 
 
 The binding site of VIPR2 and Molecule 6 is pictured in Figure 13. Residues on 
TMs 2, 3, 5, 6, and 7 interact with Molecule 6. To test the validity of our binding site we 
suggest two mutations: Gln210Ala and Glu360Ala. Additionally we note that an ideal 
ligand for this binding site would be able to form charged interactions with both Arg172 
and Glu360. 
 
Figure 13. VIPR2 bound to Molecule 6. (A) Predicted structure binding site overview.  
(B) Predicted structure pharmacophore. (C) Strongest interactions between the protein 
and ligand (kcal/mol). The quite large molecule 6 inserts itself vertically between TMs 2, 
3, 5, 6, and 7.  
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Conclusion 
 In this work, we predict the structures and small molecule binding sites of nine 
class B1 GPCRs: calcitonin gene-related peptide type 1 receptor (CALRL), corticotropin-
releasing factor receptor 1 (CRFR1), glucagon receptor (GLR), gastric inhibitory 
polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP1R), pituitary 
adenylate cyclase-activating polypeptide type I receptor (PACR), parathyroid 
hormone/parathyroid hormone-related peptide receptor (PTH1R), vasoactive intestinal 
polypeptide receptor 1 (VIPR1), and vasoactive intestinal polypeptide receptor 2 
(VIPR2). The nine receptors all share two conserved hydrogen bond networks: R2.46-
E3.50 and R/K6.37-Y/F7.57. Additionally, most of the receptors have these interactions: 
R2.46-Y3.53 (six), H2.50-E3.50 (six), N3.43-A/S2.56 (five), K/R2.60-Q7.49, and 
K/R2.60-G/S/E/N7.46. Our small molecule binding sites are consistent across the class 
B1 family, with primary interactions occurring with TMs 3 and 7. We suggest mutation 
studies to test the validity of our binding poses, as well as suggest characteristics of 
optimal ligands for targeting these binding sites. The information obtained from this 
study is well-suited for utilization in the design of drugs targeting class B1 GPCRs, or for 
further optimization of the ligands docked here. 
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Appendix 
Bihelix/Combihelix Results 
 
The structure highlighted in yellow was used for Superbihelix. 
Table A1. Top 10 structures from Bihelix/Combihelix for CALRL  
(CRFR1 Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 0 -499.8 -361.0 
0 0 0 0 120 -60 0 -495.0 -356.3 
0 -90 0 -30 90 -60 0 -491.0 -353.3 
0 0 0 0 180 0 0 -473.0 -357.7 
0 0 0 0 90 -60 0 -505.9 -349.8 
0 0 0 0 0 -90 -30 -485.2 -350.6 
0 0 0 0 0 -90 0 -463.0 -362.5 
0 -90 0 120 120 -30 0 -493.8 -346.4 
0 -90 0 -30 90 -30 0 -469.6 -347.3 
0 0 0 0 0 -30 -30 -459.2 -350.1 
 
Table A2. Top 10 structures from Bihelix/Combihelix for CRFR1  
(CRFR1 Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 0 -481.1 -440.1 
0 -90 0 0 0 30 0 -459.1 -420.8 
0 -90 0 0 0 180 0 -432.3 -416.9 
0 0 0 0 -60 0 0 -416.6 -401.5 
0 0 0 0 0 30 0 -411.4 -419.0 
30 0 0 0 0 0 0 -451.0 -389.6 
0 -90 0 0 0 0 0 -417.3 -384.8 
0 0 0 0 -30 0 0 -413.5 -389.7 
90 0 0 0 0 0 0 -436.8 -391.3 
-30 0 0 0 0 0 0 -440.0 -402.6 
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Table A3. Top 10 structures from Bihelix/Combihelix for GLR (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 -30 0 -503.2 -400.0 
0 0 0 90 0 -30 0 -494.4 -392.3 
0 0 0 0 0 -120 0 -478.7 -392.4 
0 0 0 90 0 -120 0 -471.1 -383.1 
0 0 0 0 0 30 0 -458.5 -388.3 
0 0 0 120 30 -30 0 -475.6 -379.6 
0 0 0 0 0 0 0 -463.0 -379.1 
0 0 0 90 0 30 0 -458.2 -379.5 
0 0 0 180 0 -30 0 -462.0 -364.3 
0 0 0 90 0 -90 0 -449.8 -382.4 
 
Table A4. Top 10 structures from Bihelix/Combihelix for GIPR (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 0 -315.6 -400.5 
0 0 0 0 0 -60 0 -311.7 -413.1 
0 0 0 0 0 -30 0 -311.2 -391.2 
0 0 0 0 0 -150 0 -296.3 -398.8 
0 0 0 120 30 0 0 -307.8 -388.2 
0 0 0 0 30 0 0 -294.1 -395.1 
0 0 0 0 0 30 0 -304.5 -382.9 
0 0 0 0 0 -90 0 -291.0 -373.1 
0 0 0 0 30 -120 0 -277.4 -383.3 
0 0 0 0 0 60 0 -280.4 -371.7 
 
Table A5. Top 10 structures from Bihelix/Combihelix for GLP1R (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 -30 0 -463.5 -417.0 
0 0 0 0 0 -120 0 -428.4 -395.8 
0 0 0 30 30 -90 0 -428.5 -385.0 
0 0 0 30 0 -30 0 -441.1 -376.6 
0 0 0 30 30 -30 0 -439.7 -367.8 
0 0 0 0 30 0 0 -424.3 -374.0 
0 0 0 180 0 -30 0 -421.4 -375.2 
30 0 0 0 0 -30 0 -420.1 -366.3 
0 0 0 0 0 0 0 -406.0 -376.6 
0 0 0 0 0 0 -60 -410.3 -367.1 
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Table A6. Top 10 structures from Bihelix/Combihelix for PACR (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 30 0 -580.5 -417.6 
0 0 0 0 0 0 0 -548.4 -415.3 
0 0 0 0 90 0 0 -548.3 -404.5 
-30 0 0 0 0 0 0 -540.4 -395.4 
0 0 0 0 30 0 0 -535.6 -416.6 
0 0 0 0 30 -90 0 -528.9 -396.5 
0 0 0 180 0 -30 0 -539.8 -376.8 
0 0 0 0 0 -60 0 -520.5 -388.6 
0 0 0 0 0 -90 0 -517.9 -390.6 
0 0 0 180 0 0 0 -517.8 -376.6 
 
Table A7. Top 10 structures from Bihelix/Combihelix for PTH1R (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 150 30 -120 0 -399.9 -372.6 
-90 0 0 0 0 0 0 -394.7 -400.9 
0 0 0 0 0 0 0 -394.1 -396.4 
0 0 0 150 30 0 0 -393.3 -395.8 
0 0 0 150 0 0 0 -388.7 -378.6 
0 0 0 0 0 -90 0 -387.8 -378.6 
0 0 0 0 90 0 0 -390.8 -350.3 
0 0 0 0 0 -30 0 -384.4 -388.6 
0 0 0 150 30 60 0 -384.0 -375.0 
-30 0 0 180 0 0 30 -374.5 -351.4 
 
Table A8. Top 10 structures from Bihelix/Combihelix for VIPR1 (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 0 -478.9 -408.4 
0 0 0 0 90 0 0 -475.7 -398.0 
0 0 0 180 0 -90 0 -448.4 -361.2 
0 0 0 0 0 -90 0 -437.9 -369.8 
0 0 0 120 0 -90 0 -437.7 -369.9 
0 0 0 0 0 -30 0 -430.9 -378.0 
0 0 0 0 30 -90 0 -423.0 -376.1 
0 0 0 0 30 -30 0 -430.0 -353.6 
0 0 0 180 0 30 0 -418.3 -376.3 
0 0 0 0 30 120 0 -422.8 -354.4 
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Table A9. Top 10 structures from Bihelix/Combihelix for VIPR2 (GLR Template) 
Eta (η) Charged 
InterHelical 
(kcal/mol) 
Neutral 
InterHelical 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 0 -434.1 -390.8 
0 0 0 180 30 0 0 -434.2 -371.7 
0 0 0 0 30 -30 0 -423.5 -361.1 
0 0 0 0 0 -30 0 -436.9 -349.1 
30 90 0 0 30 -90 0 -441.3 -343.1 
0 0 0 120 30 0 0 -422.6 -352.7 
0 0 0 0 90 0 0 -416.7 -353.7 
0 0 0 180 0 0 0 -416.9 -350.6 
0 0 0 0 0 -120 0 -433.0 -341.7 
0 0 0 30 0 0 0 -411.6 -358.5 
 
 
Superbihelix/Supercombihelix Results 
 The structure highlighted in yellow was used for analysis and docking. 
 
Table A10. Superbihelix/Supercombihelix results for CALRL 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
-10 0 0 0 0 0 0 15 0 0 -30 15 15 15 15 0 0 0 15 -30 -15 -592.6 278.2 -445.0 258.0 
-10 -10 0 0 0 0 -10 0 0 0 -15 15 30 -15 15 0 0 0 15 -30 0 -556.8 263.8 -423.8 257.5 
-10 -10 0 0 0 0 -10 0 0 0 -30 15 30 -15 15 0 0 0 15 -30 0 -548.2 252.0 -413.4 238.6 
-10 -10 0 0 0 0 -10 0 0 0 -30 0 -15 -15 15 0 0 0 15 -15 0 -530.3 290.3 -424.5 249.3 
-10 0 0 0 0 0 0 15 0 0 -30 0 15 15 15 0 0 0 15 -30 -15 -560.3 293.2 -412.2 280.3 
-10 -10 0 0 0 0 -10 0 0 0 -15 0 30 -15 15 0 0 0 15 -30 0 -526.6 263.3 -412.0 273.0 
-10 0 0 0 0 0 0 15 0 0 -15 0 15 15 15 0 0 0 15 -30 -15 -568.8 287.3 -416.5 288.8 
-10 -10 0 0 0 0 -10 0 0 0 -30 0 -15 -15 15 0 0 0 0 -15 0 -527.1 294.0 -423.1 248.5 
-10 -10 0 0 0 0 -10 0 0 0 -15 0 -15 -15 15 0 0 0 0 -15 0 -526.3 298.4 -427.5 254.1 
-10 0 0 0 0 0 -10 0 15 0 -30 15 30 -15 15 -15 0 0 15 -30 0 -523.1 273.0 -400.3 253.4 
Angles are with respect to the starting structure built from the CRFR1 template. 
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Table A11. Superbihelix/Supercombihelix results for CRFR1 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 -10 0 0 0 -15 0 15 0 0 0 0 0 0 0 15 -533.2 28.5 -483.7 -98.8 
-10 0 0 0 0 0 -10 0 15 0 0 0 0 -15 0 0 0 0 0 0 0 -524.9 32.2 -485.7 -98.8 
-10 0 0 0 0 0 -10 0 0 0 15 0 -15 0 0 0 0 0 0 -15 0 -534.5 55.5 -492.4 -82.2 
0 0 0 0 0 0 -10 0 0 0 15 0 15 0 0 0 0 0 0 0 15 -512.7 33.0 -458.8 -84.8 
-10 0 0 0 0 0 -10 0 0 0 -15 0 15 0 -15 0 0 0 0 0 15 -494.3 28.6 -459.5 -82.0 
-10 0 0 0 0 0 -10 15 15 0 15 0 0 0 0 0 0 0 0 0 0 -503.0 52.9 -477.7 -62.4 
0 0 0 0 0 0 -10 0 0 0 0 0 15 0 0 0 0 0 0 0 15 -500.6 59.8 -453.8 -84.0 
0 0 0 0 0 0 -10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -527.8 88.4 -482.1 -76.9 
-10 0 0 0 0 0 -10 0 0 0 0 0 15 0 -15 0 0 0 0 0 15 -491.3 29.6 -448.2 -88.6 
-10 0 0 0 0 0 -10 0 15 0 15 0 0 0 0 0 0 0 0 0 0 -496.1 38.6 -452.2 -58.5 
Angles are with respect to the starting structure built from the CRFR1 template. 
 
 
Table A12. Superbihelix/Supercombihelix results for GLR 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 -10 -10 0 -10 10 10 -30 0 0 -30 15 15 0 0 0 0 15 -30 -15 0 -524.1 114.9 -418.8 32.2 
0 -10 -10 0 -10 -10 0 0 -15 0 -30 0 15 -15 15 0 -15 0 -15 -60 0 -520.9 116.1 -432.9 63.5 
0 -10 -10 0 -10 0 0 -15 0 0 -30 -15 15 30 0 0 0 15 0 -15 0 -512.6 113.6 -418.3 72.7 
0 -10 -10 0 -10 -10 0 0 -15 0 -30 0 15 0 15 0 -15 0 0 -45 0 -528.3 120.7 -415.0 82.1 
0 -10 -10 0 -10 0 0 0 -15 0 -15 -30 15 0 15 0 -15 0 -15 0 0 -520.8 88.6 -400.7 71.5 
0 -10 -10 0 -10 10 10 -15 0 0 -15 15 15 0 0 0 0 15 -30 -15 0 -506.9 96.6 -409.5 38.3 
0 -10 -10 0 -10 0 0 0 0 0 -30 -15 15 0 0 0 0 -15 -15 0 15 -506.2 75.9 -409.4 72.9 
0 -10 -10 -10 -10 10 10 -15 0 0 -30 15 15 0 0 0 0 0 -30 -15 0 -508.3 102.5 -403.5 45.7 
0 -10 -10 0 -10 10 10 -15 0 0 -30 15 15 0 0 0 0 15 -30 -15 0 -506.6 98.5 -401.4 26.8 
0 -10 -10 -10 -10 0 0 -15 0 0 -30 -15 15 30 0 0 0 0 0 -15 0 -507.7 105.6 -405.0 72.0 
Angles are with respect to the starting structure built from the GLR template. 
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Table A13. Superbihelix/Supercombihelix results for GIPR 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 -10 -10 0 -10 0 10 -15 0 0 -30 0 15 -30 0 0 0 15 -15 0 15 -349.9 -399.4 -452.6 -803.5 
0 -10 -10 0 -10 0 0 0 -15 0 -30 -15 0 0 15 0 0 15 -15 -15 0 -354.7 -402.5 -432.9 -760.1 
0 -10 -10 0 -10 0 10 -15 0 0 -15 -15 30 -15 0 0 0 0 -15 -15 15 -354.0 -400.8 -419.1 -768.8 
0 -10 -10 0 -10 0 0 15 -15 0 -15 -15 0 0 15 0 0 0 -15 -15 0 -347.4 -412.0 -420.2 -774.9 
0 -10 -10 0 -10 0 0 0 -15 0 -15 -15 0 0 0 0 0 0 -15 -15 0 -349.3 -417.2 -421.8 -763.7 
10 -10 -10 0 -10 0 0 0 -15 0 -15 -15 0 0 0 0 0 0 -15 -15 0 -350.6 -420.6 -414.4 -773.7 
0 -10 -10 0 -10 0 0 0 0 0 0 -15 0 0 0 0 0 0 -15 -15 0 -363.8 -388.6 -428.5 -759.3 
0 -10 -10 0 -10 0 0 -15 -15 0 -15 -15 0 0 15 0 0 0 -15 -15 0 -354.4 -418.0 -409.3 -765.5 
-10 -10 -10 0 -10 0 10 -15 0 0 -30 0 15 -30 0 0 0 15 -15 0 15 -336.0 -391.3 -434.5 -781.9 
0 -10 -10 0 -10 0 10 -15 0 0 -30 -15 30 -15 0 0 0 0 -15 -15 15 -359.8 -380.0 -437.7 -749.4 
Angles are with respect to the starting structure built from the GLR template. 
 
 
Table A14. Superbihelix/Supercombihelix results for GLP1R 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 -10 -10 0 -10 0 10 0 -15 0 -15 -15 30 -15 0 0 -15 0 -15 0 15 -492.8 103.3 -415.5 -14.0 
0 -10 -10 -10 -10 -10 0 15 -15 0 -15 -15 15 -15 0 0 0 0 15 0 15 -487.9 80.0 -414.5 8.4 
0 -10 -10 0 -10 0 10 0 -15 0 -15 -15 15 -15 0 0 -15 0 -15 0 15 -489.8 119.8 -411.6 6.6 
0 -10 -10 0 -10 0 10 0 -15 0 -15 -15 30 -15 0 0 -15 0 0 0 15 -477.6 105.4 -406.3 0.3 
0 -10 -10 -10 -10 0 10 0 -15 0 15 -15 30 -15 0 0 -15 -15 15 0 15 -469.7 100.9 -414.1 -9.1 
0 -10 -10 0 -10 0 10 0 -15 0 -15 -15 0 -30 15 0 -15 0 -15 0 15 -487.7 130.1 -415.5 14.5 
-10 -10 -10 0 -10 0 10 0 -15 0 -15 -15 30 -15 -15 0 -15 0 15 0 15 -491.9 105.3 -409.9 29.1 
-10 -10 -10 0 -10 0 10 15 -15 0 -15 -15 0 -30 -15 0 -15 0 -15 0 15 -500.8 124.7 -413.3 38.2 
0 -10 -10 -10 -10 -10 0 0 -30 0 -15 -15 15 -15 0 0 0 -15 15 0 15 -489.7 101.4 -401.6 38.7 
0 -10 -10 0 -10 0 10 15 -15 0 -15 -15 15 -15 0 0 -15 0 -15 0 15 -478.0 114.6 -399.1 24.9 
Angles are with respect to the starting structure built from the GLR template. 
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Table A15. Superbihelix/Supercombihelix results for PACR 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 0 0 0 0 0 10 -15 0 0 -30 0 0 -15 0 0 0 0 15 0 15 -596.5 329.1 -432.6 238.9 
0 0 0 0 0 0 10 15 0 0 -30 0 0 -15 0 0 0 0 15 0 15 -611.1 338.9 -450.1 244.1 
0 -10 -10 -10 -10 0 0 -15 -15 0 -15 15 30 30 0 0 0 15 15 0 0 -577.9 344.5 -423.3 226.6 
0 0 0 0 0 0 0 -15 0 0 -15 0 15 15 0 0 0 0 15 0 0 -567.3 349.1 -423.8 229.6 
0 0 0 0 0 0 0 -15 0 0 -15 0 15 15 0 0 0 15 15 0 0 -571.0 354.9 -432.3 249.3 
0 0 0 10 0 0 0 -15 0 0 -30 0 0 0 0 0 0 -15 15 0 0 -570.2 351.6 -426.2 260.2 
0 0 0 0 0 0 0 -15 0 0 -15 0 15 15 0 0 0 30 15 0 0 -566.4 355.2 -422.2 261.8 
0 0 0 0 0 0 0 -30 0 0 -30 0 0 15 0 0 0 0 15 0 0 -569.4 341.2 -403.9 252.2 
0 0 0 0 0 0 0 -15 0 0 0 0 15 15 0 0 0 0 15 0 0 -568.9 348.8 -407.3 258.7 
0 0 0 10 0 0 0 0 0 0 -30 0 0 15 0 0 0 -15 15 0 0 -560.1 364.0 -430.6 246.6 
Angles are with respect to the starting structure built from the GLR template. 
 
 
Table A16. Superbihelix/Supercombihelix results for PTH1R 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 -10 -10 0 -10 0 10 0 -15 0 -30 -15 15 -30 15 0 -15 0 -15 -30 30 -519.6 -93.1 -429.2 -203.2 
0 -10 -10 0 -10 0 10 0 -15 0 -30 0 0 -30 15 0 -15 0 30 -15 15 -474.5 -90.8 -422.0 -198.8 
0 -10 -10 0 -10 0 10 0 -15 0 -30 -15 15 -30 0 0 -15 0 -15 0 30 -468.9 -108.2 -419.6 -208.0 
0 -10 -10 0 -10 0 10 0 -15 0 -30 0 15 -30 15 0 -15 0 15 0 30 -476.3 -72.5 -425.6 -178.0 
0 -10 -10 -10 -10 0 10 0 -15 0 0 0 15 -30 15 0 -15 15 15 0 30 -489.3 -71.1 -421.4 -168.7 
-10 0 0 0 0 0 10 30 0 0 -15 0 0 -30 0 0 0 0 15 -15 15 -476.6 -57.9 -433.7 -174.1 
0 -10 -10 0 -10 10 10 0 -15 0 -30 15 0 -30 15 0 -15 0 0 -15 30 -479.4 -56.9 -430.1 -170.8 
0 -10 -10 0 -10 0 10 0 -15 0 -30 -15 15 -30 15 0 -15 0 0 0 15 -470.5 -75.0 -418.9 -172.7 
0 -10 -10 0 -10 0 10 -15 -15 0 -15 0 0 -30 15 0 -15 0 30 -15 15 -463.2 -57.6 -424.2 -194.6 
0 -10 -10 -10 -10 0 10 0 -15 0 -30 0 15 -30 15 0 -15 0 15 0 30 -465.6 -63.8 -423.8 -174.7 
Angles are with respect to the starting structure built from the GLR template. 
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Table A17. Superbihelix/Supercombihelix results for VIPR1 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
-10 0 0 0 0 10 10 30 0 0 -15 0 0 -30 -15 0 0 0 15 -15 15 -493.5 291.3 -400.6 274.2 
-10 0 0 10 0 0 10 30 0 0 -30 0 15 -30 -15 0 0 0 15 -15 15 -488.1 309.1 -404.0 256.4 
-10 0 0 10 0 0 10 15 0 0 -30 0 15 -30 -15 0 0 0 15 -15 15 -484.6 298.8 -407.1 247.9 
0 -10 -10 -10 -10 0 10 -15 0 0 0 15 30 -15 -15 0 0 0 30 -30 15 -506.6 328.9 -390.5 272.2 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -478.9 274.9 -408.4 228.5 
-10 0 0 0 0 0 10 15 0 0 -15 0 15 -30 -15 0 0 0 15 -15 15 -481.1 308.3 -396.5 264.7 
-10 0 0 0 0 0 10 30 0 0 -15 0 15 -30 -15 0 0 0 15 -30 30 -481.5 311.2 -409.8 276.9 
-10 -10 -10 0 -10 10 0 -30 15 15 15 15 0 0 0 0 -15 -15 -15 -30 0 -499.4 338.4 -404.8 290.4 
-10 -10 -10 -10 -10 0 10 30 0 0 -30 0 0 -30 0 0 0 0 0 -30 15 -483.2 301.8 -380.6 266.0 
0 -10 -10 0 -10 -10 0 -15 -15 0 -30 -15 0 0 0 0 -15 0 0 -30 0 -480.3 324.3 -392.0 287.3 
Angles are with respect to the starting structure built from the GLR template. 
 
 
Table A18. Superbihelix/Supercombihelix results for VIPR2 
Theta (θ) Phi (φ) Eta (η) Charged 
Inter- 
Helical 
(kcal/mol) 
Charged 
Total 
(kcal/mol) 
Neutral 
Inter- 
Helical 
(kcal/mol) 
Neutral 
Total 
(kcal/mol) TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM1 TM2 TM3 TM4 TM5 TM6 TM7 
0 -10 -10 -10 -10 0 10 0 -15 0 30 15 30 -15 15 0 0 -15 15 -15 15 -537.6 398.4 -428.3 356.3 
0 -10 -10 -10 -10 0 10 -15 -15 0 -30 15 30 -15 0 0 0 -15 15 -15 15 -523.6 428.4 -414.8 377.3 
0 -10 -10 -10 -10 0 10 -15 -15 0 0 15 15 -15 0 0 0 0 30 0 15 -519.9 424.2 -409.7 374.0 
0 -10 -10 0 -10 0 10 -15 -15 0 -30 15 15 -15 0 0 -15 -15 15 0 15 -518.0 467.2 -423.6 388.6 
0 -10 -10 0 -10 0 10 -15 -15 0 -30 15 30 -15 0 0 -15 -15 15 -15 15 -511.7 473.0 -426.3 396.3 
0 -10 -10 -10 -10 0 10 -15 -15 0 30 15 30 -15 0 0 0 15 15 -15 15 -508.4 433.5 -405.3 389.7 
0 0 0 0 0 0 10 15 0 0 -30 0 0 -30 0 0 0 0 15 0 15 -535.1 476.2 -402.8 399.1 
0 -10 -10 -10 -10 0 10 -15 -15 0 -15 15 30 -15 0 0 0 15 15 -15 15 -507.8 436.3 -403.0 381.9 
0 -10 -10 -10 -10 0 10 -15 -15 0 -30 0 30 -15 0 0 -15 0 30 -15 15 -503.1 448.3 -412.9 391.2 
0 -10 -10 -10 -10 0 10 -15 -15 0 -15 15 30 -15 0 0 0 -15 15 -15 15 -506.7 475.7 -418.2 376.0 
Angles are with respect to the starting structure built from the GLR template. 
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Chapter V: 
The Full Structure and Small Molecule  
Binding Site Prediction of CXCR4,  
a Class A G Protein-Coupled Receptor 
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Abstract 
This work presents the full predicted structure and binding site of the chemokine 
receptor CXCR4. The structure was obtained through homology modeling of the 
transmembrane helices based on the β1 adrenergic receptor, along with the GEnSEMBLE 
methodology. The resulting structure is analyzed, with five interhelical hydrogen bond 
networks described: TM1-TM2-TM7+, TM2-TM3-TM7, TM5-TM6, TM3-TM4, and 
TM6-TM7. The anti-HIV drug 1t is docked to the structure with the GenDock procedure, 
revealing a binding site between Asp171 (TM4) and Glu288 (TM7). The N-terminus, C-
terminus, and loops are added, and the structure is optimized in full solvent molecular 
dynamics. The final structure is compared to the later published CXCR4 crystal structure, 
and validations of our structure and binding site predictions are performed. It is found 
that the deviations between our computational structure and the crystal structure are 
largely caused by the helical abnormalities of the CXCR4 crystal structure.  
 
Introduction 
 Chemokine receptors are class A GPCRs whose native ligands are chemokines, a 
family of small pro-inflammatory cytokines (signaling proteins secreted by cells). 
Activation of these receptors initiates a signaling cascade that involves G protein binding, 
protein kinase activation, Ca2+ mobilization from intracellular stores, and cytoskeletal 
rearrangement.1 The native ligand of CXCR4 is the chemokine CXCL12, also known as 
stromal cell-derived factor-1 (SDF-1). This protein is expressed on hematopoietic stem 
cells, leukocytes, endothelial cells, platelets, and tumor cells.2 CXCR4 and SDF-1 are 
involved in cell migration in the immune and nervous systems as well as in cancer 
metastasis.2 The importance of CXCR4 and its ligand is highlighted by the fact that 
deletion of either of their genes will result in embryo lethality.  
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 CXCR4 is also closely involved in HIV entry into cells. Viral entry begins with 
binding of the gp120 protein on the virus surface to CD4a on the host cell surface. This 
interaction causes a conformational change, thereby allowing the complex to bind to a 
chemokine receptor and trigger fusion between viral and host membranes. CXCR4 is 
implicated in the entry of T-tropic (X4) strains of HIV into host cells, which are involved 
in the later stage of HIV and cause rapid CD4+ T cell depletion and progression towards 
AIDS.3 The mechanics of HIV viral attachment and entry suggest an important role for 
CXCR4 as a potential drug target to combat the AIDS epidemic. Two main methods to 
prevent the spread of HIV via targeting CXCR4 have been designed.4 The first involves 
causing the removal of the receptor from the cell surface, which the native chemokines 
have been known to do (d in Figure 3). Several peptide derivative ligands based on the 
structure of SDF-1 have been created to prevent the spread of HIV via this method. 
However, as petides, these compounds tend to be less orally bioavailable than small 
molecule options. As a consequence the second method of fusion inhibition is now the 
target of drug design (c in Figure 3). In this method, the attachment of small molecules to 
CXCR4 influence its conformation such that the gp120 can no longer bind and trigger 
viral fusion, thereby preventing the spread of HIV infection.  A series of orally 
bioavailable, highly potent, selective CXCR4 inhibitors was designed by Novartis.2 The 
most potent ligand was 1t, which is shown below (see Figure 4).  
 In this work we predict the structure of CXCR4 utilizing the GEnSEMBLE5-6 
method of generating an ensemble of GPCR conformations. A selection of the lowest 
energy conformations are docked to 1t. The complexes with the best energies are relaxed 
via full-atom molecular dynamics. The lowest energy structure from the molecular 
dynamics is analyzed and compared to the later-published CXCR4 crystal structure.7 
                                                          
 
 
 
a The normal function of CD4 is to activate helper T cells in response to infectious particles. 
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Figure 3. Inhibition of HIV infection by chemokines.  The virus first undergoes a high-
affinity interaction with CD4 (blue) on the cell surface (a), followed by a conformation 
change that enables it to interact with an essential co-receptor, usually either CXCR4 or 
CCR5. This in turn allows the virus to fuse with the cell membrane (d). Two methods of 
fusion inhibition are (c) a conformational change preventing gp120 binding, and (d) 
causing the removal of the receptor from the cell surface.4 
 
   
 
Figure 4. CXCR4 inhibitor 1t. The protonatable nitrogens are circled in red.2 
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Methods 
 A brief overview of the methodology used for structure and binding site 
prediction is outlined below. More details for each step are given in Chapter II: 
1. Homology helix prediction - Helix lengths and locations were determined by 
secondary structure prediction servers. The helix translations (x/y, z) and orientations 
(θ, φ, η) were taken from the known crystal structures. 
2. Bihelix - Rotation of the helices in thirty degree increments (η) and calculation of the 
energies of each interacting pair of helices. 
3. Combihelix - Assembly of the seven-helical bundles and energy calculation to 
determine the best helix rotations. 
4. SuperBihelix - Sampling the θ, φ, and η angles of the top Combihelix structures. 
5. Supercombihelix- Assembly and scoring of the Superbihelix bundles. 
6. Ligand conformational search 
7. GenDock - Docking of 1t to the best structures from Supercombihelix. 
8. N-terminus, C-terminus, and loops connecting the transmembrane helices added. 
9. Molecular Dynamics - Full solvent and lipid molecular dynamics. 
The first step in the CXCR4 structure prediction was the determination of the helix 
lengths and locations. Homology helix lengths and locations were obtained using the 
secondary structure prediction servers Porter, APSSP2, and SSPRO.8-10 A consensus 
helix length and location was determined between the three servers – if two out of three 
of the servers agreed that a residue was helical in character, that residue was included in 
the CXCR4 helix. 
 Homology modeling was then used to create the helices. This process took an x-
ray crystal structure (β1, β2, and A2A)11-13, removed the loops, and split it into separate 
helices. CXCR4 was aligned to the homology GPCR based on the known Class A GPCR 
motifs. Each helix was then mutated to the correct CXCR4 residues, minimized using a 
conjugate gradient method for 100 steps, and brought back together to form a bundle. 
This was done for the β1, β2, and A2A templates. Bovine Rhodopsin was not included 
due to its low sequence identity with CXCR4.  
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After the TM regions were predicted and the homology helices constructed, the η 
angles of the helices were sampled via Bihelix/Combihelix in thirty degree increments 
(from 0-360 for each helix) two at a time, ignoring all other helices in the procedure 
known as BiHelix.5 The conformation and template with the lowest energy was selected 
from the top 1,000 energies output in CombiHelix. This structure was then further 
optimized using Superbihelix/Supercombihelix which locally sampled the θ, φ, and η 
angles. These variations of the starting structure were explored: θ (-10, 0, 10), φ (-30, -15, 
0, 15, 30), and η (-30, -15, 0, 15, 30). 6 Based on the average ranking of the neutral 
interhelical, neutral total, charged interhelical, and charged total energies, along with a 
desire to fully sample the conformational space via RMSD, six protein structures were 
selected to continue to the binding site determination. 
Next, the 1t ligand was prepared to be used in docking. A systematic torsional 
scan using Maestro’s MacroModel conformation search was run with four starting points 
of the left and right cyclohexane rings: up/up, down/down, down/up, and up/down. These 
structures were minimized and clustered according to LigCluster. Following structure 
selection and ligand preparation, the GenDock docking procedure was used on 1t with the 
six protein structures selected from Supercombihelix. The docking results were then 
analyzed based on the snap binding energies. Poses with low snap binding energy that 
also showed a diversity of binding modes were selected. Extracellular and intracellular 
loops, C-termini, and N-termini were constructed based on homology modelling to the 
template selected in Bihelix/Superbihelix.  These structures then underwent 10ns of full-
atom molecular dynamics. 
 
Results and Discussion 
Structure Prediction 
 Helix lengths were determined for CXCR4 via the secondary structure prediction 
servers. For each template (β1, β2, and A2A), the helices were then aligned via the 
conserved Class A GPCR motifs. The only exceptions were for TMs 2 and 4. These 
helices had two different alignments- the conserved motif or the conserved prolines (see 
Figure 5). Both alignments were used in the succeeding steps. 
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TM2 – Proline Alignment 
β1     74  TLTNLFITSLACADLVVGLLVVPFGATLVVRG 105  
CXCR4  70  RSMTDIYLLNLAISDLFFLLTVPFWAVDAVAN 101 
TM2 – Conserved Residue Alignment 
β1     74  TLTNLFITSLACADLVVGLLVVPFGATLVVRG 105  
CXCR4  71  SMTDIYLLNLAISDLFFLLTVPFWAVDAVANW 102 
 
TM4 - Proline Alignment 
β1     154 TRARAKVIICTVWAISALVSFLPIMM 179 
CXCR4  148 RKLLAEKVVYVGVWIPALLLTIPDFI 173 
TM4 – Conserved Residue Alignment 
β1     154 TRARAKVIICTVWAISALVSFLPIMM 179 
CXCR4  149 KLLAEKVVYVGVWIPALLLTIPDFI  174 
 
Figure 5. Two possible alignments of TMs 2 and 4 of β1 and CXCR4. The helix may 
be aligned by conserved Class A GPCR motif (LxxxD), or via the conserved Proline, 
both of which are depicted in red. Both alignments were pursued for the initial template 
generation and BiHelix/ComBiHelix structure predictions. 
 
 Following alignment, each TM bundle was built according to its respective crystal 
angles, tilts, and x/y/z coordinates. Bihelix was then run, with the result that the β1 
template with proline alignments for TMs 2 and 4 was lower energy than any of the other 
combinations. The lowest energy bundle had all zero eta rotations with respect to the β1 
crystal structure, and is depicted in yellow in Table 1. To further refine this TM bundle, 
Superbihelix was run. The number one structure had these angles: eta (0_15_0_15_-
30_0_-15), phi (15_-15_-15_-15_-15_-15_-15), and theta (-10_0_-10_10_10_-10_-10) 
(shown in yellow in Table 2). Since proteins are known to exist in a variety of low 
energy conformations, five structures other than the number one were selected from the 
top ten Superbihelix ensembles. They were chosen based on their RMSD, so that the 
sample space was adequately explored (see Table 3). 
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Table 1. Superbihelix/Combihelix results for the lowest ranked templates 
Template 
Eta Charged 
Interhelical 
Charged 
Total 
Neutral 
Interhelical 
Neutral 
Total H1 H2 H3 H4 H5 H6 H7 
β1 Proline 0 0 0 0 0 0 0 -438 522 -370 347 
β2 Proline 0 0 0 90 270 0 90 -525 653 -374 510 
β2 Conserved 0 0 0 120 270 60 60 -463 636 -357 530 
β1 Conserved 0 0 0 120 150 60 30 -428 738 -330 648 
The template selected in yellow was used for further analysis. All energies are in kcal/mol. All angles are 
with respect to their template. 
 
 
Table 2. Top Supercombihelix/Supercombihelix structures. 
Eta Phi Theta Average 
H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 Rank 
0 15 0 15 -30 0 -15 15 -15 -15 -15 -15 -15 -15 -10 0 -10 10 10 -10 -10 32 
0 15 0 15 0 30 -15 -15 -15 -15 -15 -30 0 -15 0 0 -10 10 0 -10 -10 54 
0 15 0 15 -15 30 -15 -15 -15 -15 -15 -30 0 -15 0 0 -10 10 0 -10 -10 58 
30 15 0 15 15 0 0 0 -15 30 -30 -30 -15 0 -10 -10 -10 0 0 -10 -10 63 
30 15 0 15 -15 0 0 -15 -30 0 -15 -30 0 0 -10 -10 -10 0 10 -10 0 64 
0 15 0 15 15 0 15 0 0 0 -30 -30 -15 0 -10 -10 0 0 0 -10 -10 64 
0 15 0 15 0 0 15 -15 0 0 0 -30 -30 0 -10 -10 0 -10 10 -10 -10 66 
30 15 0 15 -30 0 0 -15 -30 0 -15 -30 0 0 -10 -10 -10 0 10 -10 -10 67 
0 15 0 15 0 0 15 0 0 0 -30 -30 -30 0 -10 -10 0 -10 10 -10 -10 67 
0 15 0 15 15 0 0 15 -15 -15 -15 -30 -15 -15 -10 0 -10 10 0 -10 -10 69 
The structures flagged in yellow were used for docking. The pose in red was the final best structure after 
docking and molecular dynamics. 
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Table 3. RMSD matrix of the top 10 structures from Supercombihelix. 
 
The structures flagged in yellow were docked to using GenMSCDock. 
 
 
 
Binding Site Prediction 
 Conformations of 1t were generated using Maestro’s systematic torsional scan 
with four starting points. This resulted in 46 conformations of 1t. All of these structures 
were docked to the six protein structures from Supercombihelix. The resulting protein-
ligand complexes were scored by snap binding energy. A combination of very low snap 
binding energies (top ten for that protein conformation), along with a desire for diverse 
poses was used to select six complexes for further study using molecular dynamics. After 
10ns of MD, the best pose was chosen based on its snap binding energy after being run 
through the post-DarwinDock modules of GenDock. The pre-MD angles of this pose are 
shown in red in Table 2 and ligand binding site and cavity analysis are show in Figure 6. 
As the figure shows, two hydrogen bonds are formed between the protein and the 
ligand’s charged nitrogens. 
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Figure 6.  Binding pose and unified cavity analysis for the rank 1 protein-ligand 
complex. Note the two hydrogen bonds that the charged nitrogens on the ligand make to 
the protein residues Glu288 and Asp171. All energies are in kcal/mol. 
 
 
 
Structure Analysis 
 The best CXCR4-1t structure after molecular dynamics had five sets of 
interhelical hydrogen bonds: TM1-TM2-TM7+, TM2-TM3-TM7, TM5-TM6, TM3-
TM4, and TM6-TM7. The 1.50-2.50 conserved Class A GPCR hydrogen bond motif was 
present in our structure: N56(TM1)-D84(TM2). However, CXCR4 is unable to make the 
Class A 3.42-2.45-4.50 hydrogen bond network because the 3.42 and 2.45 residues are 
not the typically conserved residues.  
The largest region of interlocked hydrogen bonds occurred in the intracellular 
portion of primarily TMs 1, 2, and 7 (with a few residues in TMs 3, 4, 6). These are 
shown in Figure 7A. Notably, there is a strong salt bridge between R77(TM2) and 
E153(TM4). The second largest hydrogen bond network occurs at the extracellular ends 
of TMs 2, 3, and 7, as is shown in Figure 7B. Finally, three smaller sets of interactions 
occur between TMs 5-6, 3-4, and 6-7 as shown in Figure 7C, D, and E respectively. 
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Figure 8. Interhelical interactions in the rank 1 CXCR4 structure. In the table _X 
indicates the transmembrane helix that the residue is a member of. All energies are in 
kcal/mol. (A) TM1-TM2-TM7+ hydrogen bond network, (B) TM2-TM3-TM7, (C) TM5-
TM6, (D) TM3-TM4, and (E) TM6-TM7. 
 
 
Comparison to the CXCR4 Crystal Structure 
After the previous work was completed, a crystal structure of CXCR4 bound to 1t 
was published (PDB ID: 3ODU).7 The TM bundle and ligand RMSDs can be found in 
Figure 9. The resolution of the structure was 2.5Å, and the T4 lysozyme fusion protein 
was inserted at the intracellular junction of TMs 5 and 6. Here we compare our structure 
to that of the CXCR4 crystal. Figure 9 presents an overview of the CXCR4 crystal: 
CXCR4 predicted structure comparison. The average TM RMSD between the two 
structures was 4.0 Å. Also, the predicted ligand pose itself was not in same location – our 
ligand targeted Asp171 and Glu288, while the crystallized ligand interacted with Asp97 
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and Glu288. The possible reasons for the discrepancy between the predicted and the 
crystal structure are discussed below.  
 
Figure 9. Comparisons of the predicted and x-ray crystal CXCR4 structures. (A) 
RMSD comparison of each helix of our structure to the x-ray crystal structure. All RMSD 
are backbone RMSD, with the TM bundle aligned, unless specified otherwise. (B) Our 
structure (blue), x-ray crystal structure (red and atom colored). (C) Our structure (blue), 
x-ray crystal structure (red).    
 
 
 To dissect the potential flaws in our structure prediction procedure, we validated 
each of them sequentially: 
 First, we explored Bihelix/Combihelix. When these programs were run on the 
crystal helices and template, we obtained an all-zero conformation as our number 1 
structure by the average neutral interhelical, charged interhelical, neutral total, and 
charged total energy ranks, our usual scoring methodology (Table 4). We then ran our 
Superbihelix/Supercombihelix procedure, which showed the crystal all-zero rotations in 
the top five (specifically fourth), a rank sufficiently high to validate those procedures as 
well. The number one structure from Superbihelix/Supercombihelix only showed a single 
variation from the crystal structure: the φ angle of TM4 was 30° (Table 5). 
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Table 4. Top Bihelix/Combihelix structures for the CXCR4 crystal helices 
Eta 
H1 H2 H3 H4 H5 H6 H7 
0 0 0 0 0 0 0 
0 0 0 0 0 60 0 
0 0 0 0 0 0 0 
0 0 0 30 0 0 0 
0 0 0 0 330 0 0 
0 0 0 0 0 60 330 
0 0 0 0 270 0 0 
0 0 0 330 0 0 0 
0 0 0 330 270 0 0 
0 0 0 0 330 60 0 
 
Table 5. Top Superbihelix/SuperCombihelix structures for the  
CXCR4 crystal helices 
Theta Phi Eta 
H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 
0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 30 0 -15 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 0 -15 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 15 0 -15 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 -30 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 30 15 -15 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 30 15 -30 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 -15 -15 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 -30 0 0 0 0 0 0 -15 0 0 0 
 
 Next, we considered the docking procedure. First, we looked at the ligand 
conformation prediction. Out of our 46 ligand conformations, two ligands were generated 
with RMSDs of less than 1Å between the computational and crystal ligands. Next, we 
considered the docking procedure itself. We docked the crystal ligand conformation to 
the crystal protein structure. We obtained several poses with an RMSD of less than 1Å to 
that of the crystal structure, including the number one structure by snap binding energy 
(Figure 10). This structure also interacted with the correct residues on CXCR4 – Asp97 
and Glu288. Therefore, neither our ligand conformation nor our docking procedure was 
the reason for our relatively poor results. 
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Figure 10. Binding site of the GenDock docking of the crystal 1t to the crystal 
protein. The crystal pose is shown in gray. All energies are in kcal/mol. 
 
This left us with one final comparison to make – that of the actual helix structures, 
particularly any atypical helices that overwound or unwound compared to a canonical 
alpha helix, since our procedure does not account for this. As discussed in the Steven 
paper, the CXCR4 structure is remarkably different from the other structures that have 
been crystallized thus far (Figure 11). The largest deviations, as mentioned in the 
Stevens paper, are:14 
1. The EC end of helix 1 is shifted toward the center of the bundle by 9Å compared to 
β2 and by 3Å compared to A2A. 
2. Helix 2 is overwound near Pro92, which allowed both Asp97 and the conserved 
Asp84 to face inwards to interact with the ligand and form the 1-2-7 conserved 
hydrogen bond network, respectively. 
3. Both ends of helix 4 show large variations (~5 and 3Å) from those of the other 
GPCRS. 
4. The EC end of helix 5 is one turn longer in CXCR4. 
5. Helix 6’s EC end is shifted by ~3Å from β2 and A2A. 
6. The EC end of helix7 is two turns longer. 
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Figure 11. Comparison of four class A GPCR crystal TM bundles: CXCR4 (purple), 
β2AR (yellow), A2AR (green) and rhodopsin (pink).  
 
These deviations indicate that using any sort of homology helices or homology bundle 
template would result in large errors in the TM bundle predictions. We experienced this 
issue, as did all of the GPCR Dock 2010 participants.14 No one did particularly well on 
the bundle, and most of the ones who were close on the ligand binding site used 
mutagenesis information to pick their best poses, and as such were not the sort of ab 
initio methods that we strive for.  
 While our structure was not identical to that of the CXCR4 crystal structure, it is 
important to keep several things in mind. First of all, GPCRs exist in several low lying 
conformational states.15 The helix changes necessary to optimally bind to the ligand 1t, 
while preserving the class A GPCR conserved TMs 1-2-7 interactions and also crystallize 
(with T4L between TMs 5 and 6), is one conformation of CXCR4. Our methods may 
have obtained another viable conformation of CXCR4. 
Conclusion 
 We present here the full structure of CXCR4 bound to 1t, a small ligand 
antagonist that is a potential anti-HIV drug. The structures are predicted through the 
GEnSeMBLE and GenDock methodologies. Our structure showed strong hydrogen 
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bonds between 1t and Asp171(TM4) and Glu288 (TM 7), as well as large interhelical 
hydrogen bond networks: TM1-TM2-TM7+, TM2-TM3-TM7, TM5-TM6, TM3-TM4, 
and TM6-TM7. While our final structure showed significant deviations from the later 
published CXCR4 crystal structure, we are able to validate all steps of our methodology, 
including: Bihelix/Combihelix, Superbihelix/Supercombihelix, and GenDock. However, 
since our methodology did not allow for helix shapes to vary, and the crystal structure 
helices were deformed greatly from canonical alpha-helices, our structure differed from 
that of the crystal structure. We suggest that our structure is another valid low-lying 
structure of CXCR4, just not the one which was favored by the crystallization conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
References 
1. Ueda, S.; Oishi, S.; Wang, Z. X.; Araki, T.; Tamamura, H.; Cluzeau, J.; Ohno, H.; 
Kusano, S.; Nakashima, H.; Trent, J. O.; Peiper, S. C.; Fujii, N., Structure-Activity 
Relationships of Cyclic Peptide-Based Chemokine Receptor Cxcr4 Antagonists: 
Disclosing the Importance of Side-Chain and Backbone Functionalities. J Med Chem 
2007, 50 (2), 192-8. 
2. Thoma, G.; Streiff, M. B.; Kovarik, J.; Glickman, F.; Wagner, T.; Beerli, C.; 
Zerwes, H. G., Orally Bioavailable Isothioureas Block Function of the Chemokine 
Receptor Cxcr4 in Vitro and in Vivo. J Med Chem 2008, 51 (24), 7915-20. 
3. Hatse, S.; Princen, K.; Bridger, G.; De Clercq, E.; Schols, D., Chemokine 
Receptor Inhibition by Amd3100 Is Strictly Confined to Cxcr4. FEBS Lett 2002, 527 (1-
3), 255-62. 
4. Wells, T. N.; Power, C. A.; Shaw, J. P.; Proudfoot, A. E., Chemokine Blockers--
Therapeutics in the Making? Trends Pharmacol Sci 2006, 27 (1), 41-7. 
5. Abrol, R.; Bray, J. K.; Goddard, W. A., 3rd, Bihelix: Towards De Novo Structure 
Prediction of an Ensemble of G-Protein Coupled Receptor Conformations. Proteins 2012, 
80 (2), 505-18. 
6. Bray, J. K.; Abrol, R.; Goddard, W. A., 3rd; Trzaskowski, B.; Scott, C. E., 
Superbihelix Method for Predicting the Pleiotropic Ensemble of G-Protein-Coupled 
Receptor Conformations. Proc Natl Acad Sci U S A 2014, 111 (1), E72-8. 
7. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; 
Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; 
Stevens, R. C., Structures of the Cxcr4 Chemokine Gpcr with Small-Molecule and Cyclic 
Peptide Antagonists. Science 2010, 330 (6007), 1066-71. 
8. Pollastri, G.; McLysaght, A. Porter: A New, Accurate Server for Protein 
Secondary Structure Prediction. http://distill.ucd.ie/porter/ (accessed 1/14). 
9. Raghava, G. P. S. Apssp2 : A Combination Method for Protein Secondary 
Structure Prediction Based on Neural Network and Example Based 
Learning. http://www.imtech.res.in/raghava/apssp2/ (accessed 1/14). 
10. Bryson, K.; McGuffin, L.; Marsden, R.; Ward, J.; Sodhi, J.; Jones, D. Protein 
Structure Prediction Servers at University College 
London. http://bioinf.cs.ucl.ac.uk/psipred/ (accessed 1/14). 
11. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; 
Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C., High-
Resolution Crystal Structure of an Engineered Human Beta2-Adrenergic G Protein-
Coupled Receptor. Science 2007, 318 (5854), 1258-65. 
12. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. 
C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F., Structure of a Beta1-
Adrenergic G-Protein-Coupled Receptor. Nature 2008, 454 (7203), 486-91. 
13. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, 
J. R.; Ijzerman, A. P.; Stevens, R. C., The 2.6 Angstrom Crystal Structure of a Human 
A2a Adenosine Receptor Bound to an Antagonist. Science 2008, 322 (5905), 1211-7. 
14. Kufareva, I.; Rueda, M.; Katritch, V.; Stevens, R. C.; Abagyan, R., Status of Gpcr 
Modeling and Docking as Reflected by Community-Wide Gpcr Dock 2010 Assessment. 
Structure 2011, 19 (8), 1108-26. 
111 
 
15. Kenakin, T.; Miller, L. J., Seven Transmembrane Receptors as Shapeshifting 
Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug 
Discovery. Pharmacological Reviews 2010, 62 (2), 265-304. 
 
